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ABSTRACT
The NPM~ALK fusion gene, formed by the t(2;5)(p23;q35) in non-Hcdqktn's
lymphoma encodes a 75kDa bvbrtd protein that contains the amino-terminal
118 amino acid residues of the nucleolar phosphoprotein nucleophosrr.ln
(NPM) joined to the entire cytoptasmlo portion of the receptor tyrosine
kinase, anaplastic Iymphuma klnase (ALK). The transforming ability of NPM-
AU< is demonstrated and it is shown that oncogenesis by the chlmaeric
protein requires the activation of its kinase function as a result of
ollgomerisation mediated by the NPM segment. NPM-AU{ was shown to
homo-cltqomertee In vivo In addition to hetero-ollqornerlslnq with normal
NPM. Irnmunostalning experiments of the t(2;5)-contalning lymphoma cell line
SUp ..M2 revealed NPMMALKto be localized within both the cytoplasmic and
nuclear/nucleolar compartments. An intact NPM seqment is absolutely
required for NPM··ALK-mediat(~d oncogenesis, as indicated by the
observation that three diff,re:nt NPM·ALK mutant proteins lacking non-
overlapplnq portions of the NPM segment each failed to form complexes,
lacksd kinase activity In vivo, and failed to transform oe;'s. However, NPM
could be replaced In the tuson protein with the portion of the unrelated
tranelocated promotor region (TPR) protein that activates the TPR-MET
tusion kinase by mediating dimerlsatlon through Its leu,.lne zipper motif. This
engineered TPR-ALK hybrid protein, whloh transformed cells with essentially
Iv
equivalent potency to NPM-ALK, was localised within the cytoplasm of cells.
These data indicate that the nuclear/nucleolar localisation of NPM-ALK,
which probably occurs because of transport via shuttling activity of NPM, is
not required for oncogenesis. Further, the activation of the truncated AU<
protein by a;. comt ' ~ely heterologous oligomel'isation domain suggests that
the functionally important role of the NPM segment of NPM-Al.K In
transformation is restrtcted to the formation of kinase-active ollgomet's and
does not involve the alteration of ncnnal NPM function.
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1 • INTRODUCTION
1.1 Signalling by receptor tyrosine kinases
Protein t~(rosinekinases are present in all multicellular organisms where they
play crucial roles In signal transduction. One class of these enzymes,
designated intracellular klnases includes members of the SRC family of
kinases which are associated with inl J iarts of the cell membrane, as well
as members of the ABL kinase family, which encode intracellular proteins
with the ability to localise to the nucleus (Rodrigues and Park, 1994). The
second class, tyrosine kinase receptors, Include the epidermal growth factor
receptor (EGFR), insulin receptor (IR). irlsulln-lil<e growth factor 1 receptor
(IGF-1 R), platelet-derived growth factor receptors (PDGFR), fibroblast
growth factor receptors (FGFR), hepatocyte growth factor receptor
(HGFRlMET), and the tropomyosin receptor kinase (TRK) family. These
members, all of which possess single transmembrane domains separating
the extracellular domains from the intracellular domains, typically contain
one or several coples of immunoglobulin-like rsqtone, cysteine-rich domains,
or other dornalns (reviewed by Fantl et al., 1993).
Receptor tyrosine kinases are activated after etther homodimerlsatlon or
heterodlrnerlsatlon. The different lsotorrns of platelet ..derlved growth factor
(PDGF), for example, can induce the formation of different dlmeric forms of
Its receptors: wtlereas PDGF-AA Induces only PDGFAaa homodimers, PDGF-
AS induces both PDGFRua homodimers and PDGFRa~ heterodimers, and
PDGF~8B Induces all three forms of receptors. EGFR can homodlrnerlse with
itself or form heterodlrners with ERBB2, a receptor tyrosine kinase with
extensive homology to EGFR (Coussens e~al., 1985; Yamamoto et al.,
1986), The insulin and Insulin-like growth factor 1 receptor family represent
a marked exception to the above mechanism. These receptors exist in the
oell membrane as dlsultlde-bondsd homodlrners and heterodimers of
receptor subunits. This means that ligand bindln~ does not induce receptor
dlmerlsatlon, but presumably causes I!\ conformational change In the eXisting
dlmerlc structure, leading to receptor activation. In addition,
autophosphorylated tyrosine residues In the receptor are not essential tor
binding of downstream components in the signal transduction pathways.
Instead, the receptor phosphorytates insulin receptor substrate 1 (IRS-i),
which mediates subsequent interactions with proteins containing SRC
homology 2 (SH2) domains (reviewed by Heldln, 1995).
Receptor dlmerlsatlon is followed by' receptor autophosphorylatlon, which
principally occurs by one receptor molecule phosphorylating the other In the
elmer. This autophosphorylatlon occurs on two different classes of tyrosine
2
residues. On the one hand, autophosphorylation is typically seen on a
conserved tyrosine residue within the kinase domain(s). In the cases of the
insulin receptor and MET, pbosphorylatlon of tyrosine residue at this and
neighbouring sites leads not only to an increase In the kinase activity but
also to phosphorylation of other sites in the receptor or its substrates. The
initialising event in autophospnorylatlon is presently unknown. One possibility
is that the monomeric receptor has a low basal kinase activity, sufficient to
phosphorylate and activate the companion receptor after dtmertsetlon. This
reaction would then be followed rapidly by reciprocal phosphorylation.
Alternatively, interactions between intracellular domains of the dtmerlsed
receptors may induce conformational changes that promote Increased
kinase activity. It should be emphasised that not all receptors are regulated
by phosphorylation in the kinase domain; for example, the conserved
tyrosine residue In the kinase domain of EGFR does not appear to be
autophosphorylated (reviewed by Heldln, 1995).
The second class of autophosphorylatlon sites are often located outside the
kinase domaln(s) and serve the important function of creating docking sites
for downstream signal transduction molecules containing SH? domains.
Numerous proteins Involved In signal transduction are modular, htwing
structures suggesting that they were "cobbled together from a tool kit of
3
functional domains", and some of these domains mediate protein-protein
associations (Mayer and Baltimore, 1993). Two such domains are SH2 and
SRC homology 3 (SH3) which appear to play critical roles in the formation
of signalling complexes (figure 1.1). SH2 domains, consist of about 100
amino acids folded in such a way as to form a binding pocket for a
phosphorylated tyrosine and the Immediately surrounding amino acids. SH3
domains, consisting of approxlrnatsly 50 amino acids, are prollne-rloh and
recognise one or more proline residues. Such regions are found in a wide
variety of protein contexts: In association with catalytic domains and the
non-receptor protein tyrosine kinases; within structural proteins such as
fodrin or tensln: and In a group of small adaptor molecules that consist
almost entirely of SH2 and SH3 dornalns, including CRK, NCK and growth
factor receptor-bound protein 2 (GRB-2) (Mayer and Baltimore, 1993;
Pawson, 1995).
Although SH3 domains frequently co-exlst with SH2 domains, they are also
found In separate contexts. They have been identified in the products of
several genes in budding and fission yeast, and have been linked to
processes such as budding (SEMi and ABP1), cell fusion (FUS1), and RAS
guanine nucleotide exchange (OD025). SH2 domains have not been Identified
In yeast, which also lack SRO-related tyrosine klnasee. Evidence suggests
4
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Figure '1.1. Interaotlon of a representative receptor tyrosine kinase with
SH2/SH3 signalling molecules. After receptor activation and subsequent
autophosphorylatlon, signal transduction molecules are recruited. Proteins
containing SH2 domains associate with speoltlo phosphotyroslnes of the
receptor thus providing for downstream signal transduotlon molecules
(modified from Johnson and Vaillancourt, 1994; Pawson and Schlessinger,
1993).
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that SH3 domains are Involved 1nthe control of small RAS-like guanine
nucleotide-binding (G) proteins. The most compelling results relate to the
cloning of the SBP1 gene, whose product binds directly to the SH3 domains
of c-ABL. This short proline-rich peptide contains a sequence distinct from
the SH3-binding site that is related to a group of proteins with OTPase-
activating activity toward members ()f the RHO/RAC family of small G
proteins. Similar proline-rich sequences were identified in sen-or-sevenless
(SOS) which was initially identified as a component of a signalling pathway
initiated by tyrosine kinase receptors (Pa.wson and Gish, 1992; Pawson and
Schlessinger, 1993).
Receptor autophosphorylatlon acts as a molecular switch to create binding
sites for the SH2 domains of cytoplasmic signalling proteins, which
consequently become targets for activation. SH2 domains directly
recognize phosphotyrcslne, but for high affinity binding to occur the
phosphotyroslne must be embedded within a specific amino acid sequence.
Residues immediately carboxy-terminal to the phosphorylated tyrosine,
especially tlhose at the +1 and +3 positions, appear to provide selectivity
for specific SH2 domains, such as those found In SRC and LCK. As
mentioned earlier, the Insulin receptor employs a variation in this stra.tegy.
Its autophosphorylatlon stimulates receptor kinase activity, but there is no
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evidence that such activation induces strong association with signalling
proteins. Instead I the Insulin receptor interacts with a 1B5kDa protein
known as IRS-1, which contains many potential tyrosine phosphorylation
sites that lie within consensus SH2..blnding elements (Sun et al., 1991).
Tyrosine phosphorylated IRS-1 is found in association with both GRB-2 and
the pB5 subunit of phosphatldyllnosltol 3'..kinase (PI3'-kinase). Thus, rather
than Incorporating its SH2-binding sites as an Intrinsic part of the receptor.
the insulin receptor relies on a discrete SH2-docking protein (Pawson, 1995;
Pawson and Gish, 1992).
Another example by which targets of receptor tyrosine kinases transmit
biological signals includes the SH2-contalning protein p91. PDGF can induce
the transcription factor SIF to bind to a regulatory element, SIE, In the o-
FOS promotor. Protein p91, which was Identified as a component of the
interferon-a Inducible transcription compier, ISGF-3, apparently mediates
these events. Tyrosine phosphorylated p91 accumulates In the nucleus
where it can bind the SIE element and promote transcription (reviewed in
Kazlauskas, 1994).
In the nematode Caenorha.bditis elegans, the SEM-5 gene encodes a small
protein with the structure Shd-SH2-SH3 that appears to link a receptor
tyrosine to the RAS pathway (Pawson and Glsh, 1992) The human GRB~2
protein Is similar Iii structure and {unction to the S£M~5 product, suggesting
that this pathway has been highly conserved in evolution (Lowenstein at al.,
1992; Pawson and Gish, 1992). GRB..2 binds EGFR d:rectly through tyroolne
1068 and indirectly through the SRC homology and. collagen (SHC) site. It
also interacts with PDGFR directly through tyrosine 716 and indirectly
through binding to a phosphorylated SYP/protein tyrosine phosphatase 1D
(PTP1D) (Heldin, 1995; Schlessinger, 1994).
GRB-2 binds directly to murine 80S 1, a guanine nucleotide releasing factor
for RAS GTPase, through two SH3 domains. 81 j is also associated with
activated receptor tyrosine kmases that bind GR8 ..2, and with the GRB~2
binding protein SHC. Overexpression of Drosophila SOS stimulates
morphologic transformation of rodent fibroblasts (Egan et al., 1993). GRB-
2 Can also bind tyrosine kinase substrates through its SH2 domain
(Lowenstein et al., 1992). This bltunctlonallry allows GR8 ..2 to serve as an
adaptor molecule that integrates upstream signallers (the klnases) with
elements two steps further down the cascade (80S) (Egan et al., ·1993).
Signal transduction pathways become more complex when one conslderc
that pB5 Plr::r·klnasa,phosphcopase C gamma (PLOy) and GTPas9wactivating
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protein (GAP) all have two SH2 domains and can themselves be
phosphorylated on tyrosine upon receptor dlmerlsatlon. The binding "t
tyrosine kmase receptors to SH2-00ntall1lng proteins affords at least three
potential signalling mechanisms: (a) alteration of subcellular localisation, (t,~
contormatlonal changes, and (0) phosphorylation by the. activated receptor
(Mayer and Baltimore, 1993).
SH2 domains have other functions besides those already rnendonsd.
Members of the c-SRC family are held In a c ataiyt!cally Inactivr~ state l)y
phosphorylatlon of a carboxy-terminal 1:yrosl\,H~re$idu(;'}. MuUl'{lon of this
tyroslne to phenylalanine renders these proteins CH1CCI(j€lnic t,y Inc:reasll1gthe
~:lna$e activity of a-SRC members in vitro anu it1 vivo. The SH2 dornaln of
SRC has moderately high affinity for its phoepnorylated carnoxy-terrnlnal
p sptids, and has been proposed to Interact in rte with this site to mask the
catalytic domain. On thr ' -ner hand, when tbe protein Is constitutively
aottve, mutations in the SH2 domain generally decrease transforming
aotivity, Indicating a second, positive role tor this motif. Deletion or mutation
of the SH3 domain In non-receptor tyrosl'l€) klnases generally leads to
oncogenlo actIvation of the protc-oncoqsne kinase, suggesting that the SH3
domain blnds to an lnhlbl.or of kinase activity (Mayer and Baltimore, 1993).
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SHO, a modular protein with a carboxy-terminal SH2 domain, also contains
a phcephotyrcslne-bmdlnq (PTB) domain on the amino terminus and a
centra! glycinEl/proline"l'ich motif with regions of homology to the <xi chain of
collagen. The PTe domain has a minimal binding region of approximately 160
amino acids and Is involved in protem-protem interactions. SHO is
presumably involved in RAS activation through its interaction with GRB·2 and
SOS. Mouse fibroblasts that overexpress SHe become transformed in
culture an<'lform tumours In nude mice. SHO, whloh is essentially
cytoplasmic, Is highly conserved and widely expressed (Pelllol et al., 1992;
van der Gear land Pawson, 1995)
1.2 Oncogonlc aetlvatlon of receptor tyrosine kinases
Many tyrosine kinase receptors are activated by moans other than ligand
binding, for example, activation after the binding of antibodies, where the
Fab fragments are usually Inactive (Heldln, 1995). Insertion of an extra
cysteine residua in the extracellular juxtamembrane r(~gionof EGFR leads to
formation of a constitutively active dlrnerlo receptor (Sorokin at al., 1994).
Purthermore, mutated forms of some receptor tyrosine klnases have been
Identified as transforming oncogenes. Frequently, the activating mechanism
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Is a gene rearrangement that leadls to production of a hybrid protein
containing the kinase domain of the receptor fused to ~ novel protein
sequence. The arnlno-termlnal fusion partners are often domains of
proteins that normally undergo oligQmerlsation. Examples include sequences
from the translated promotor region (TPR) fused to MET, non-muscle
tropornyosln (TPM3) fused to TRK, the regulatory subunit of the cyclic AMP·
dependent protein kinase (Ria) tused to RET, nucleopbosmln (NPM)
sequences fused to the anaplastic ~ymphoma kinase (ALK), and TEL fused
to PI)GFR~ (Golub at al., 1994; Martin-Zanca. et al., 1986; Morris et al., 1994;
Park at al., 1986i Rodrigues and Park, 1994; Takahashi et al., 1985) (table
1.1 ).
Receptor tyrosine klnases can also become oncogenic throuJh the
acquisition of point mutations that result In constltutlve aotlvatlon of the
catslytlc domain (Yarden and Ullrich, '1988). This mechanism Is exemplified
I)y the NEU (ERBB2) oncogene product, which contains a single amino acid
exchange In the transmembrane region, that promotes receptor
ollqomerlsatlon, and by the oolony-stlmutatlnq factor 1 receptor (C81=-1 R)
WhOSl9 transtormlnq activity derives from a mutation In the extracellular
domain (Rouslssl at al., 1988; Weiner at al., 1989; Woolford at al., '1988).
1 1
-- .=- ..
Gene rearrf.ingemant Chromosomes involved Oancer Aeferflnces-
NPM-ALK t(2;5)(p23: q35) Non-Hodgkin's lymphoma a
iPR·MET t(1:7)(q25; q21-31) Gastric:carcinoma b,o,d
TPM3-TAK inv(1 )(q31: q2S·24) Colon & thyroid carcinoma ('l,f,9,h
1
l'PR·TRK Inv(1)(q25: q23-24) ihyrold carcinoma I
1fG.'TPJ< t(1 ;3)(q2S·24; q?) Thyrvllf carcinoma j
L'7a-iAK t(1 j9)(q2S-24; q34) Breast oarclnoma k,l
TEL·PDGFjl t(5;12)(iI33; pi3) Myeloid leukaemia m
D10S170·RET Inv(10)(q',I1.2; q21) ,'hyrold carcinoma n
Ria-RET t(10j17)(q11.2:q23-24) Thyroid carcinoma 0
Table 1.1. Oncogenic activation of some receptor tyrosine kineses.
Tyrosine kineses can become constitutively activated by gene
rearrangements through fusion with novel proteins that norn.ally undergo
oligomerlsatlon. a (Morris at at, 1994), b (Park et al., 1986), c (Miranda
at al., 1994), d (Soman at al., 1991), e (Martin~Zanc!a 18t al., 1986), f
(Radice at al., 1991), 9 (Morris at al., 1991), h (sozz! et al., 1992), I
(Greco at al., 1992), j (Greco et al., 1995), k (Kozma at al., 1988), I (Yon
at al., 1989), m (Golub et al., 1994), n (lshlzaka at al., 1992), 0
(Bongarzone et al., 1993).
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Although the mechanism for oncoqenlc aotlvatlon of receptor tyrosine
kinases may vary, they invariably lead to constltutlve activation of normally
tightly regulated enzymes (Rodrigu9f' and Park, 1994).
1 .2.1 TPR..MET
The human TPR gene, which maps to chromosome 1, encodes two
alternatively spliced transcripts • one encoding a protein of 726 amino acids
and the other q protein of 2094 amino acids. Both of these ubiquitously
expressed proteins have been localised to the cytoplasmic surface of the
nuclear pore complex and both are predicted to have extensive regions of
a-helices and several stretches of heptad repeats which Is characteristic of
proteins with a coiled c )l conformation. TPR is weakly homologous to the a..
helical domains of tropomyosin, speotrln, larnlnln 81, the Drosophila glued
protein and the tall region of myosin heavy chain (Byrd at al., 1994; Chan at
at, 1987; Mitchell and Cooper, 1992; Mitchell and Cooper, 1992; Park et aI.,
1986).
MET, the receptor for the hepatocyte growth factor/scatter factor
(HGF/SF), in a heterodlmar of 190kDa conslstlnq of a 50kDa ()(,subunit
associated with a 140klJa ~ subunit. Multiple forms of this recaptor tyrosine
1 SI
kinase have been identified (Rodrigues et al., '1991; Vigna et al., 1994). MET
is related to the kinase domains of the human insulin receptor, EGFR and tne
murine v"ABL oncoprotein (Dean at aI., 1985; Reddy at al., 1983). The MET
proto-oncogene, which is predominantly expressed in fibroblast and
epithelial cell lines, maps to human chromosome 7q21-S1 (Park et aI.,
1986). The tight genetic linkage of the MET locus with the hereditary genetic
disease cystic fibrosis, led to tbe assignment of the cystic fibrosis gene to
the 7q21-31 reqlon (Clean at al., 1985; White et al., 1985).
The HGF/SF ligand and MET regulate growth, motility and morphogenesis of
cells In vltro. In mouse embryos deficient In MET, the diaphragm and limb
bud are 110 longer colonised by myogenlo precursor cells, consequently
skeletal muscles of the limbs and diaphragm do not form. These
ebnormalttles appear to be responsible for death during embryonic
development (Bladt et at, 1995). Moreover thr; Mer gene was found to be
amplified in oel! lines derived from poorly dlfferentiajted human gastric
carcinomas and in spcntanecusly transformed murine NIH3T3 fibroblasts
(Cooper et al., 1986; (~iordano et al., 1988; Giordano et al., 1989).
Arnptlrlcatlon In these celts does not appear to be accompanied by any gene
rearrangement, but It is associated with MET overexpresslon In 60% of
osteosarcomas, for example (Ferraclnl et al, 1995; Rodrigues (It al., 1991).
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Another mechanism for oncogenic activation of MET entails its fusion with
TPR, as seen in human osteogenic sarcoma cells treated in vitro with the
clastogenlc carcinogen N-methyl-N'-nitronitrosoguanidine. The chimaeric
protein generated by chromosomal translocation has a molecular mass of
60 to 65kDa and contains the amino-terminal sequenc:e from TPR and the
carboxy-terminal sequence from MET (Chan at al., 19197;Park et aI., 1986).
The extracellular and transmembrane domains and a portion of the
cytoplasmic region of MET are deleted (Park et al., 1EI87). In the 523 amino
acid TPR-MET, 142 TPR codons are followed by 381 h~lframeMET amino acid
residues (Chan et al., 1987).
Deletion of TPR from TPR-MET abolishes the transforrnlnq ability of this
protein. A leucine zipper region within the 'TPR sequences mediates
dlrnerlsatlon of TPR-MET and is thus responsible for constitutive activation
of the MET kinase. As a result of gene rearrangement, 'rPR-MET Is localised
to the cytoplasm (Rodrigues and Park, 199:3). In addition to activating MET,
TPR Is also 1mown to activate the ssrlne/threonlne kinase RAF, and the
recaptor tyrosine Idnase TRK (Graco et el., 1992; King at al., 198H).
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1.2.2 TPM3-TRK
The TRK family of receptor tyrosine klnases, Including TRK (or TRKA), TRKe
and TRKe, mediate the trophic effects of the nerve growth factor (NGF)
family of neurotrophins (8arbacid, 1994). TRK, the receptor for nerve
growth factor is essential for the development of the peripheral and central
nervous systems. Mice deficient in TRK have severe sensory and
sympathetic neuropathies and most die within a month of birth (Kaplan et
al., 1991; Smeyne et al., 1994).
The TRK proto-oncocene encodes two lsotorms (790 and 796 amino acids
each) that yield glycosylated proteins of 140kDa (BarJ<eret al., 1993;
Martin-Zanca et a!., 1989). They differ In the presence of six amino acids
located in the extracellular domain (Barbacid, 1994). The 796 residue
protein Is expressed mainly In neuronal cells, while the 790 amino acid
Isoform is found primarily in non-neuronal cells (Barker et al., 1993).
Both TPMs and TRI< are located on the long arm of chromosome 1: the
former at 1q31 and the latter at either 1q23-24 or 1qS2ri41 (Miozzo at al.,
1990; Morris et al., 1991; Radice et al., 1991). Thus, the generation of the
hybrid protein Is due to an lntrachromcsomal rearrangement.
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TPM3..TRK was cloned from a human colon carcinoma by DNA mediated
transformation of NIH3T3 cells. The 70kDa TPM3-TRK protein consists of
641 amino acids, 221 of which are derived from TPM3 with the remaining
420 representing the TRK receptor tyrosine kinase (Martin-Zanca €It al.,
1986). Oncogenic activation of TRK has been attributed to the called coil
structure of TPM3 (Barnes et aI., 1989; sodek et aI., 1972). Both the TPM3
and the TRK portions are required for proper transformation (Coulier et al.,
1989), Activated TRK has also been found in papillary thyroid carcinoma
and breast carcinoma (Kozma et al., 1988; Sozzi et al., 1992; Zlemiecki et
al., 1990).
In addition to its constitutive activation by fusion with TPM3, TRI< can also
be activated by 11.1slonwith TPR, L7a or TFG sequences on Its 5' end. Two
forms of the chlmaerlc TPR·TRK oncoprotein have been identlfled. In each,
the amino-terminal sequences of TPR are fused to the TRK kinase domain.
One Is a protein of 55kDa consisting of i99 amino acids from TPR and 383
residues from TRK (Greco et al., 1992). The second form encodes a protein
of 150kDa that contains additional TPR sequences fused to the same
subset of Tf={Ksequences present in TPM;3~1·RI(Barbacld, 1993). Since the
genes for both proteins are located on chromosome 1, TPR..TRK is
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generated by an lntrachromosomal rearrangement. In the L7a-TRK fusion
product, the amlno-termlnal sequence is contributed by the first 41 amino
acids of the ribosomal large subunit protein L7a, while the carboxy-terminal
sequence consists of the last 420 codons of TRK (Kozma et al., 1988;
Ziemiecki et al., 1990). This 44kDa protein is localized to the cytoplasm and
nucleoli (Ziemiecki at al., 1990). Finally, the TRI<gena may fuse with an
unknown 5' partner, termed TRK fused gene (TFG) owing to a t(1 ;3)
chromosomal translocation. The product of this rearrangement, a 68kDa
cytoplasmic protein, contains 199 amino acids from TFG and 471 residues,
from TRK (Greco et al., 1995).
1.2.3 RET fusion proteins
Most of the proto-oncogenes examined thus far are expressed during
embryonlc development, often in very defined spatial and temporal patterns
that suggest functions In the growth and maturation of specific tissues
(Dressler, 1994). Naturally occurring mutations In the receptor tyrosine
kinase gene RET, are associated with the human diseases multiple endocrine
nsoplasla type 2A ar1J familial medullary thyroid carcinoma (Mulligan et al.,
1994; Mulligan et al., 1993; Takahashi and Cooper, 1987) Iri these patients
the mutations occur in the extracellular domain C'f RET, where they alter
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highly conserved cysteine residues. These mutations may result in the
constitutive activation of RET by by-passlnq the need tor ligand binding
and/or facilitating drmerlaatlon of unbound receptors (Dressler, 1994).
T~I, lliT gene is frequently activated in papillary thyroid carcinomas, either
by an inversion. inv(10)(q11.2q21), that generates D10S170-RET, or by a
chromosomal translocation, t(10;17)(q11.2;q23-24), that gives rise to Rla-
RET, where the regulatory subunit of cyclic AMPNdependent protein kinase A
(RIa) Is fused to RET (Bongarzone at al., 1993; lshlzaka et al., 1989;
lshlzaka et al., 1992; Ishizaka et al., 1990; Takahashi and Cooper, 1987).
80th types of constitutively activated ReT genb,' encode two Isoforms.
Under non ..reducing conditions, the two RI((-RET lsoforms occur as both
homodimers and heterodimers (Bongarzone et al., 1993).
Mice deficient In RET completely lack neurons In the oesophagus" storaach
and Intestines, consistent with the observed expression ot RET in the vagal
neural crest cells that migrate from the hIndbrain to populate the
mesenteric plexus of the gut. The absence of gastrointestinal peristalsis in
RET knockout mice Is similar to the symptoms of the human congenital
megacolon (Hirschsprung's disease), which has also been linked to the RE:T
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locus on chromosome 1Oq11.2 (Angri~t et al., 1993; Dressler, 1994;
Lyonnet et aI., 1993).
1.2.4 Nucteophoemtn-anaplaetlc lymphoma kinase (NPM~ALK)
Nucleophosmln (NPM)
The human NPM (also known as 823, nutramin or NOS8) cDNA encodes a
nucleolar protein of 294 amino acids and has a reported molecular mass
ranging from 32 to 38kDa. This ubiquitously expressed protein has a
putative metal binding site, two acidic amino acid clusters, and two nuclear
localisation signals (Chan et al., 1989) (figure 1.2). Under native conditions
NPM is a hexamer of 220kDa consisting of 4a and 2~ monomers organised
in a head-to-tall fashion (Yung and C~an, 1987). 80th the amino- and
carboxy ..terminal domains of NPM are essential for oligomerisatlon.
Replacement of methlonines at amino acid positions .'5, 7, 9 with leuolnes or
deletion of five amino acids at the carboxy terminus abolishes
oligomerlsatlon (Liu and ruan, 1991). On the other hand, Herrera and
colleagues suggest that the carboxy terminus of NPM is not essential for
ollgomerisatlon (Herrera at aI., 1996). NPM is expressed at higher levels in
tumour calls than In normal cells, is highly phosphorylated during mitosis,
and is a substrate for cdc2 (Chan et aI., 1989; Feuerstein et al., 1990;
Olson et al., 1974; Peter et al., 1990).
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Figure 1.2. Schematic representation of the NPM, ALK and tI,a ohlmaerlo
NPM-ALK oncoproteln. NPM which Is composed of 294 amino acids, contains
a putative metal binding domain (MB), two acidic regions (AC) and two
nuclear localisation signals (NLS). ALI< Is a tyrosine kinase receptor
consisting of 1620 amino acids with a si~nal peptide (SP), transmembrane
domain (TM)and a juxtamembrane region {dM). The NPM-ALK chimaera Is
composed of the 118 amino-terminal amino acids of NPM fused to 562
residues from ALK.
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Rat NPM exists as two alternatively spHr.ed tsotorms, these coding for
psptldes 823.1 (292 amino acids) and 823.2 (257 amino acids) (Chang and
Olson, 1989). The two isoforms are expressed at different levels in tissues,
823.1 being more abundant. In addition, protein 823.1 is found
predominantly in the nucleolus, while 823.2 appears to be present In the
cytoplasm (Wang Elt al., 1993). Whereas B23.1 can bind RNA, single..
stranded DNA and double-stranded DNA, 823.2 is unable to bind double-
stranded DNA (Wang et al., 1994).
Although the function of NPM is not well defined, the protein Is thought to be
involved In ribosome assembly and transport (Chan and Chan, 1995). In
vitro studies have demonstrated that NPM binds to ANA, DNA, the HIV REV
protein, transcription factor YY1 and nucleolar protein p120 (Dumbar et al.,
1989; Fankhauser et al., 1991; Feuerstein at at, 1990; Inouye and Seto,
1994; Valdez at al., 1994) This nucleolar phosphoprotein, which has a high
a.ffinity for peptldes containing I<aryophllllc sequences or nuclear localisation
Signals, was found to shuttle between the nucleolus and the cytoplasm
(Borer dt al., 1989; Szebeni et AI., 1995). The above evidence suggests that
NPM may have multiple functions.
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Anllp'tl~\tlc lymphoma kinase (AI_te)
The ALK tyrosine kinase receptor (1620 amino acids) has a 26 residue
signal sequence, an extracellular domain of 1004 amlno acids, a
transmembrane regh:m of 28 amino acids, a 64 residue [uxtarnembrane
segment, a kinase c nnaln of 254 amino acids, and an umJsually long 244
residue oarboxy-termlnat tail (figure 1.2). After glycl')sylatkm, the ALK
precursor (molecular mass of 177kDa) assumes its mature form as a
2001<Da single·l~hain receptor (Morris et al., 1996).
ALK shows greah?st amino acid similarity to Insulin receptor subfamily
members such as Ieukocyts tyrosine kinase (LTI<; 64%), TRI< (38%), ROS
(37%), the p chains of the insulin-like growth factor receptor \(37%) and
insulin receptor (36%) (Morris at al., 1.994). In addition, AU( contains paired
autophosphorylatlon sites (y1292 y12(3) typical of members of the Insulin
receptor subtamily (Morris at al., 1996).
F'our different AI..K transcripts were found In tissues and cells from various
sources, Messenger RNAs of 6.5 and 8kb were expressed to a high degree
in rhabdomyosarcoma cell lines and in small intestine, and to a lesser degree
in brain, colon and prostate. A 61<btranscript was identified in placenta and
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foetal liver, while 4.4 and 6i<bmRNAs were detected in testis. No ALK
transcripts were apparent in haematopoletlc cells (Marris et at., 1994). In
situ hybrldlsatlon studies to localise the expression of mouse ALK, showed
that ALK transcripts were limited tID the central and peripheral nervous
systems In this experimental model (Morris et al., 1996) (table 1.2),
NPM..ALK
Large-cell lymphomas constitute appr/ ...~tely 25% of all paediatric and
adolescent non-Hodqkln's lymphomas. About one-third of these tumours
have a t(2;5)(p23;q35) chromosomal rearrangement that generates the
NPM-ALK oncoproteln, This malignancy, which arises mainly from activated
T-cells, Invades and destroys normal lymph nodes, soft tissues,
gastrointestinal tract, skin, lungs and bone marrow (Morris et al., 1994). By
classical histochemical examination, .the neoplastic cells have large Irregular
nuclei, prominent nucleoli and abundant cytoplasm. They express CD30/Ki-1,
a cytokine receptor tor a ligand related to tumour necrosis factor, and
Inte7leukln-2 (Downing and Morris, 1994; Morris at el., 1994). Cell lines with
the t(2j5) express both the normal 1.61<bNPM transorlpt and a 2.4I<b
transerlpt, while those without the fuslon gene express only the 1.6kb
transcript. NPM presumably contributes an active promotor to drive
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'-----~~~-~------------------------------__,
Age ALK expression~---------- ---------------~
Day..10 embryos No transcripts
Oay-11 embryos Primitive spinal cord
Cranial ganglia
Day-12 embryos, Splnul cord
Cranial ganglia
Perlventrloular zone around third ventricle
Day-14 embryos Neuronal cells around third ventricle
Olfactory nerves
Ventral splnat cord
Day-15 (& older) embryos Thalamlc nuclei
Cranial ganglia
Sympathetic chain
Ventral spinal cord
Newborn Thalamic region
Adult Thalamic region
Table 1.2. Tissue distribution of murine ALK transor'pts within developing
embryos. The pattern of ALK expression was determined by an in situ
hybrldlsatlon technique (Morris at al., 1996).
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expression of the ALK kinase domain, especially considering that ALK Is not
expressed in lymphoid cells (Morris et aI., 1994).
Neither anaplastic morphology nor CD30 expression reliably Identify NPM-
ALK-positlve lymphomas (Downing et al., 1995). In one study, cases without
C030 and/or NPM·ALK exprusslon were classified as anaplastic large cell
Iymphoma.s (ALCLs): conversely cases without anaplastic morphology were
found to express NPM-ALK (Downing and Morris, 1994). Waggot and co-
workers found the t(2;5) In all Kt-t-posltlve cases of ALCLs, while Pulford
and colleagues documented NPM..ALK expression in about half of their CD30-
positive lymphoma cases (Pulford et al., 1996; Waggott et al., 1995).
Herbst and associates Identified NPM-ALK expressed predominantly in the
ALCLs of young patients, with Elmbergel' and colleagues reporting that
t(2;5) I~unique to ALCLs (Elmberger et al., 1995; Herbst at aI., 1995). NPM·
ALK Is also expressed In soma patients with Hodgkin's lymphoma (Bullrlch at
aI., 1994; Orscheschek et al., 1995). To resolve these conflicting
obeervations, Sandlund and co-workers devised a model to explain the
apparent overlap of ALr.,l...~,KI..1 positive large-cell non-Hcdgkln's lymphomas
and NPM-ALK containing lymphomas (Sandlund et al., 1994) (figure 1.3).
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Pigure 1.3. Schematic diagram illustrating the overlapping features of
ALCLs, OD30+ large cell non..HodgKln'e lymphomas (LC NHLs) and NPM~ALK
i.! 'pre~tldg LC NHLs (from Sandlund at aI., 1994).
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The NPM-ALK oncoprotein has 118 amino acids from NPM on its amino
terminus and 562 residues 'from ALK on Its carboxyl end (figure 1.2). Since
the NPM amino terminus is retained in the chlmaerlc construct, and is
necessary for NPM homo-oflqomerlsatlon, it is plausible to sliggest that
NPM-ALK may exist as either a homo-oligomer or in association with wild·
type NPM (Liu and Chan, 1991). Indeed, homo-oligomerisation of NPM·ALK
may constitutively activate the NPM-ALK kinase domain (figure 1.4). The
two nuclear localisation signals found In NPM are deleted In the fusion
protein, predicting 1 cytoplasmic locallsatlon Tor the latter protein. Potential
phosphorylation sites tor protein kinase C and a putative metal-binding
domain resldo within the NPM portion of the chimaera, while possible binding
sites for Pl3'·klnase, IRS·1 and SHC are present in the ALK ..derived
sequences (Morris at al., 1994) (figure 1.5). The amino acid residues at
positions 564 to 567 (NPTys67)are suggested to be a SHC binding site,
whereas the residues at amino acid poshons 153 to 156 (NPNy166)are
predicted to be bind IRS..1 (Fujimoto et a!., 1996).
NPM sequences have been found with fuslon partners other than ALK,
including the retinolc acid receptor 0: (RARa) in a patient with acute
promyelooyttc leukaemia and the t(5;17)(q32jq12) translocation. Two
alternatively spliced forms of NPM..RARa, NPMs ..RARa and NPML -RARa were
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Figure 1.4. Model for the constitutive aotlvatton of NPM·ALK. Receptor
tyrosine klnases are activated by ligar."l, '11ediatadditnerisatlon which results
in the trans-phosphorylation of receptor subunits, and the binding of the
tyrosine phosphorylated receptor to intracellular substrates. NPM..ALK Is
thought to be a cytoplasmic protein that oligomerises through domains
present In the arnlno terminus of NPM. This ollgomerlsatlon would be
predicted to result In the constitutive activation of the of the ALK kinase
domain and its interaction with and phosphorylation of downstream
substrates (from Downing and Morris, 1994).
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PRFILLET"MAGGDLKSFLRETRPRPSQPSSI,AMLDLLHVARDIACGCQYL 300
••EENHFIHRDIA.ARNCLLTCPGPGRVAKIGDFGM~.RDIYRASYYRKGGCAM 350
LPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLE 400
~ -,
FVTSGGRMDPPKNC..?GPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDP 450
:::.:0:.=
DVINTALPIEYGPLVF.EEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAA 500
PPPLPTTSSGKAAKK~TAAEVSVRVPRGPAVEGGHVNMAFSQSNPPSELH 550
KVHGSRNKP'l1SLWN.IL.~GSWF·rEKPTKKNl\TP:tAKKEPHDRGNLGLEGSCT 600
VPP~ATGRLPGASLLLEPSSL'rANMKEVPLFRLRHFPCGNVNYGYQQQG 650
LPLEAATAPGAGHYEDTILKSKNSMNQPGP 680
f~igure 1.5, Deduced amino acid sequence of human NPM"ALK. Asterisks
('k ) depict putative protein kinase C phosphorylation sites, 4-l4 represents
the NPM..ALK junction. ~ +! indicates the boundaries of the kinase domain,
•• shows the paired tyrosine autophosphorylatlon site typical of receptor
tyrosine kinases in the insulin receptor subfamily. The boxed area is a
putative metal binding domain. Underlined motifs represent possible IRS·1
and SHe binding sites, respectively. The double underlined amino aolds
Indicate a putative PI3'·kinase binding region.
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Identified. Both proteins were expressed in the patient's leukaemic cells
together with wild-type RARa (Redner et al., 1996). In cases of
myelodysplastic syndrome and acute myeloid leukaemia with the
t(3;S}(q2S.1 ;qS4) translocation, NPM is fused to myelodysplasia/myeloid
leukaemia factor 1 (MLF1), a protein of unknown tunc:tion. NPM-MLF1 is
expressed in t(3;5}-positive leukaemia cells but wild-type MLF1 is not
(Yoneda-Kato at al., 1996).
1.3 Objectives
Chromosomal rearrangements resulting In the constitutive activation of
receptor tyrosine klnases have been shown to be oncogenic. A t(2;5)
translocation found in about 10% of paediatric non-Hodqkln's lymphomas
results in the expression of the nucleophosmln-anaplastlo lymphoma kinase
(NPM-ALK) fusion protein. This chimaera consists of the amino terminal 40%
of the nucleolar phosphoprotein, NPM, fused to the intracellular portion of
ALK, a tyrosine kinase receptor. Despite some knowledge of structural
features of NPM..ALK, very little Is known about the manner 1,1 which this
chlmaerlc protein transforms cells. Native NPM exists as an oligomer, so
that ollgornerlsatlon of the NPM portion of the chimaera might be expected
to activate ALK, thereby leading to malignant transformation. The work
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cutllned in this thesis is Intended to test this hypothesis; deletion mutants of
NPM-ALK were constructed and tested for ollqomerlsatlon, phosphorylation
and cellular localisation in relation to transtormatlor ..
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2. MATERIALS AND METHODS
2.1 Materials
Specific reagents used In this study were obtained from the sources
indicated in the text. All other reagents were of analytical grade.
2.2 Cell culture
Six cell lines were used in this study: (1) Fisher rat 31"3 (Fr3T3), an
Immortalised but non-tumorlqenlc rat fibroblast line (provided by Morag
Park, McGill University, Montreal, Canada), (2) NIH3T3, a mouse fibroblast
line (provided by Martine Roussel, St. Jude Children's Research Hospital,
Memphis, TN, USA), (3) 293T, an SV~40transformed human kidney cell line
(provided by Martine Roussel) (4) COS-7, an SV-40 transformed monkey
kidney cell line (provided by David Shapiro, St. Jude Children's Research
Hospital, Memphis, TN, USA), (5) SUP-M2, a human lymphoma nell line
containing the t(2;5) (provided by Stephen Smith, University of Chicago
Medical School, IL, USA), and (6) K562, a human leukaemia. cell line (source
unknown) (Lozzto and t.ozzlo, 1977; Morgan at al., 1989). Fr3r3, NIH3T3,
293T and COS-7 cells were maintained in Dulbscco's Modified Eagle's Medium
(Medlateoh, Herndon, VA, USA) supplemented with 10% foetal calf serum
(FOS; SloWhlttaker, WalkerSVille,MD, USI, I whereas SUP-M2 and K562 cells
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were grown in RPMI 1640 (BioWhittaker, WaIHer~\;lIIe,MD, USA)
supplemented with 20% FCS and 10% FCS, respectively. All cell hiles were
Incubated at 37°0 in a humidified incubator with 5% carbon dioxide. Fer
experiments, adherent cells were tryslnlzed with trypsin ..othytenedtarnlna-
tetraacstlc acid (trypsin-EDTA; Life Technologies, Gaithersburg, MD, USA),
quenched with complete medium and collected by centrifugation. Cells were
then resuspended in fresh medium, counted on a haemooytometer using the
trypan-blue exclusion test for viability, and plated onto tissue culture dishes
as required (Patt~rson, 1979). Unless otherwise Indicated, all experiments
were carried out under the above-mentioned conditions.
2.3 DNA transtectlons
COS~7 cells were transiently transfected using the dlethylamlnoethyl-dextran
{DEAE-dextran) method (Mammalian Trar.steotlon Kit; Stratagene, La Jolla,
CA, USA~ Briefly, 5X105 cells were plated onto a 100mm culture dish one
day prior to transtectlon, For transfectlon, 81J.9of plasmid DNA was diluted
with phosphate-buttered saline (PBS), and DEAE·dextran added to this. Cells
were washed with PBS and the transtectlon mix added dropwise to the
centre of the culture dish, which was gently swirled to distribute the solution
evenly. Following a 15 minute incubation at room temperature, the SOlution
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was removed, tho cells washso with PBS, and fresh medium added, For
experiments cells were harvested 72 hours post-tranetectlon.
For immtmofluorec:~ence COS- 7 cells were eleotroporated with the lndicated
DNA constructs. Approxtmataly 107 cefls were resuspended in SOOIlIof RPMI
1640 supplemented with 10% FCS and put into O.4cm gap Gene Pulsar
cuvettes (Blo ..Rad, Hercules, CA, USA), To this 5fl9 of DNA was added and
allowed to rook at room temperature for 10 minutes. Cells were
electroporated with a Bio..Rad Gene Pulsar at 250V and 96011F.The cells
were rocked for a further 10 minutes, aftsr which they were plated onto
coversnps in 35mm culture dishes at various dilutions, and Incubated at
37°C for 24 to B6 hours.
2.4 Production of retrovlrat stocks
T. optimise the efficiency of transformation, several batches of 2X BES-
buffereti saline (BSS) (50mM (N, N~bl$ ':2..hydr()xyethyl)~2"
amlnoethanesulfonlc acid (8ES); Calblochem, La Jolla, CA, USA), 280mM
Naol, 1.5mM NaaHP04) rangIng in pH from 6.92 to 7.00 were prepared and
tasted as previously descrlbed (Roussel et al., 1988). In brief, :3X105 NIH3T3
calls In 35mm culture dishes were transfected using th(~calcium phosphate
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technique, with 0.1~g of pSM f(;'line sarcoma virus (FeSV) and 5119of
pBluescrlpt carrier L)NA. One day post-transleotlon each dish of cells was
thin •.~d out and maintained In Dulbecco's Modified Eagle's Medium
supplemented with 5% FCS. The foci of transformed cells were scored ~I) to
14 days after transfection. Only the buffer yielding the highest
transtormatlon efficiency, that Is the most foci, was used In subsequent
experiments.
Helper-free retrovirus was generated by transfecting 293T cells with both
\}I~~ packaging DNA (provided by Owen Witte, HHMI, University of California,
LOIs Angeles, CA, USA) and construct DNA in retroviral vector', using thA
oalclurn phosphate precipitation method (Grcahamand Van der Eb, 1973;
Peal' et al., 1993) (pers. commun. Martine Roussel, Sf. Jude Children's
Research Hospital, Memphis, TN, USA). A day prior to tranefectlon, 293T
cells were seeded out at 2x105 cells per 100mm plate in 10ml of medium.
For transfeotlon, 20f.lg of each of 'P2 and construct DNA were made up to
a final volume of 450111with delnoised water. To this 50~1Iof 2.5M calcium
chlorlde was added, followed by the addition of 500111of 2X BBS. This
solution was vortexsd and tncubated at room temperature for 20 to 30
minutes, lafter which the calcium phosphatsaDNA mix was added dropwlse
to the medium In the plates containing the HEi3Tcells. The transfeoted cells
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were Incubated for approximately 18 hours in the presence of 8% carbon
dioxide, after which they were rinsed with PBS and fresh medium was
added. After a further 6 hours incubation, a mirdmal amount of fresh
medium was added (usually 3 to 4ml). Collection of retroviral stocks was
commenced 30 hours post-transtectlon and continued every 6..12 hours for
a total of 36 hours. Viral supernatants which were kept on lee at all times,
were pooled, filtered through 0.451lm pore size filters and used to infect
Fr3TS cells. All solutlcns used for transtsctlons, excluding the DNA, were
filter sterilised through O.211mpore size filters.
2.5 Retroviral lntectlons
Fr3TS cells were seeded at a density of 2X106 cells per 100mm plate 24
hours prior to infection. For infection the msdlum was removed from cells,
and 2ml of virus supernatant contalnlnq 8~lg/ml polybrene (Sigma, St. Louis,
MO, USA) was added and allowed to incubate in the presence of 8%
carbon dioxide for 3 to 4 hours, Growth medium was then added and cells
in(',!.!b~:c;c!for a further 72 hours. At this time Fr3T3 cells were used for
transformation asssys, focus formation, G418 selection and for the
derivation of clonal cell ltnes (see sections 2.6 and 2.7).
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2.6 Transformatton assays
One day prlor to soft agar cloning, 2ml of bottom agar was poured lnto
35mm culture dishes. Noble agar (Dlfco Laboratories, Detroit, MI, UGA) was
made to 1.2% in delnonised water, autoclaved and allowed to cool to 45°0.
This was diluted 1:1 with prewarmed 2X complete lscove's Modified
Dulbecco's Medium (BioWhlttaker, Walkersville, MD, USA) yie'/dln~1a 0.6%
bottom agar in 1X Iscove's Modified Dulbecco's Medium supplemented with
15% FeS. Fr3T3 colony formation in soft agar was measured by plating
5X103 or 2X104 cells in 0.3% noble agar In Iscove's Modified Dulbecco's
Medium containing 15% FeS, onto the 0.6% bottom agar. Colony formation
was assessed 10 to 'i4 days after plating.
2.7 Focus termatton, G418 selection and derivation of clonal
cell lines
Infected Fr3TS cells were plated out In duplicate at 2X1ali cells per 100mm
culture dish. On the following day complete medium supplemented with
800).1g/ml of G418 (Geneticin; Life Technologies, Gaithersburg, MD, USA) was
added to one of the dishes containing cells. 80th sets ot cells were
maintained In culture for ,0 to 14 days. At this stage the unseleotsd plates
were stained with Giemsa (see section 2.8), while the G418 selected plates
were used for the derivation of slngleMceliclones. Briefly, sterile glasEIcloning
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rings were placed onto plaques of cells originating from a single cell, with
sterile petroleum jelly. The C'3llswithin the cylinder were trypsinlsed and
further propagated. Alternatively, where clones had formed in soft agar,
these were plucked with a pipette, trypslnlsed and also ,"Ilowed to multiply
further.
2.8 Glemsa staining
Cells were rinsed with PBS and stained with Giemsa (CMS Stain Pack;
Biochemica! Sciences, Swedesboro, NJ, USA). The stain was left on the cells
for 1.5 minutes, after which an equal volume of buffer 2 was added and left
for an additional 1.5 minutes. Cells were rinsed with PBS and allowed to dry
In an lnvsrted position.
2.9 Polymerase chain reaction (peR)
TPR-ALK and NPM·MET were generatp.dusing a three-oligonucleotide peR
method (Davis at al., 1994). l1MBNPM-ALK and L1()5'103NPM..ALK were
constructed using the thermal cycled fusion method (Kahn at al., 1990).
MS{1!9LNPM_ALK and l<P.l0RNPM..ALK were generated by peR using
oligonucleotide primers containing engineered nucleotide substitutions
designed to alter selected cedens, Other constructs wer€:' generated by
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PCR"based mutagenesis. Reaction mixtures for three-oligonucleotide peRs
contained 0.5ng of each of the two templates, 100ng of both the sense and
antisense primers, 20 to 300ng of the hybrid primer, 400~M of each of the
four deoxynucteotlce trtphosphates (Pharmacia, Plsoataway, NJ, USA), 1X
Pfu polymerase buffer and 2.5U of recombinant Pfu polymerase
(Stratagene, La Jolla, CA, USA) In SOil' reactions. The reaction mixtures for
all other PCRs contained 200ng to 1J.!gof template, O.5IlM of each primer,
200llM of each of the four deoxynucleotlde trlohosphates, 'IX Ptu
polymerase buffer and 2.5U recombinant Ptu polymerase In 50111reactions.
Templates were denatured at 95°C for 5 minutes, and thirty CYCles,each
oonslstlnq of 1 minute denaturation at 95°0, 1 minute of annealing at 50°C
and 1.5 minutes extension at 72°0 were conducted.
2.10 Ligatlontl anr,l transformations
ligations were performed using a DNA ligation kit (Stratag'1ne, La Jolla, CA,
USA). Reactions were set up containing an equimolar ratio of vector to
insert, 1mM rATP, 'IX ligase buffer and 4U of "[4 DNA ligase in a total
volume of 10J..t1.Ligation was allowed to proceed overnight at 12°C.
Subsequently, the Ilge.tlon mix was made up to 25~l!with water and the DNA
precipitated with 10 volumes of n-butanol, The speedvac dried pellet was
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redissolved in 101-1.1of water. ElectroMAX DHiOB bacteria (20).L1)(Life
Technologies, Gaithersburg, MD, USA) were pipetted into a chilled 0.2cm gap
Gene Pulser/E. coli pulsar cuvette (Bio..Rad, Hercules, CA, USA; and half of
the ligation mix added. Electroporatlons were performe.~ ." ~500V, 200.0
and 25j.1.F.Immediately after electroporation O.5ml of SOC (20g/1 tryptone,
5g/1 yeast extract, 0.5g/l sodium chloride, 2.5mM potassium chloride,
20mM magnesium chloride and 20mM glucose) was added, and the bacteria
allowed to recover at 37°C for one hour. Since all the va' . .ised in this
study contain the ampicillin resistance gene the DH10B cells were plated out
on LB agar plates (10g/1 tryptone, 5g/1 yeast extract, 10g/1 sodium
chloride and 15g/1 agar) containing 50j.l.g/ml of ampicillin.
To facilitate cloninp into the ECGJRI or Hindlll site of the retrovlral vector
pSR<xMSVtkneo (section 2.:14), llnkere were ligated to blunted cLJNAs, All
cDNAs with 5' overhangs were filled in using Klenow enzyme (Random
Primed DNA Labeling Kit; 80ehrlnger Mannhslrn, Indianapolis, IN, USA).
Subsequently lEooRI or l-lindllJ linkers were added by incuba.ting 500ng of
DNA Insert, 2j.1.9of phosphorylated linkers, 1mM rATP I 1X ligase buffer and
12U of T4 DNA ligase in a total volume of 301-1.1at 12°0 overnight. The DNA
In the linker mix was precipitated by the addition of 300mM sodium acetate,
pH 5.2, and two volumes of ethanol. This was centrifuged and the pellet
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redissolved in 1X TE (10mM Trls-HCI, pH 8 and 1mM EDTA). The cDNA Insert
with added linkers was digested with the appropriate restriction enzyme
and purified using the Geneclean II Kit (8io 101, Vista, CA, USA), and utilised
for subsequent ligations.
2.11 Plasmid :"reparations
Bacteria expressing construct DNAs were grown in LB (10g/l tryptone, 5g/1
yeast extract and 10g/1 sodium chloride) containing ,50llg/ml of ampicillin.
All plasm Ids were isolated from bacteria using Qlagen Plasm:n Kits (Qiagenj
Chatsworth, CA, USA).
2.12 DNA sequencing
Reading frames of the .;DNA oonsn uots were confirmed by In vitro
transcription and translation (see section 2..17) followed by SDSnpAGE to
demonstrate a peptide of prcdlcted size. The possibility of errors
introduced by peR was excluded by sequencing. The dldeoxy chain
termination method (Sanger at at, 19'.17) using the sequenase Version 2.0
kit (USB, Cleveland, OH, USA) was employed. Five 119 of plasmid DNA in a
volume of Bill was denatured by the addition of 2~ll of 2M NaOH and heating
to 85°C for 5 minutes. The DNA was put on ice and neutralised by adding
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1.4,.1.1of 3M sodium acetate, pH 5.2. To this O.5~ .., of single-stranded DNA
binding protein (Stratagene, La Jolla, CA, USA), 50ng primer and 40lJ.1of
ethanol were added. Following the placement at ..20°C for at least 15
minutes, the denatured DNA"primer mix was centrifuged, and the pellet
resuspended in 7111of water. Annealing of primer to DNA was performed at
37°C for 20 to 30 minutes. Tl.s labelling reaction was commenced by the
addition of 2111of 5X Sequenase buffer, 1III of 0.1 M dhhlothreitol, 2111of 1X
dGTP labelling mix, 1111of [<x-35SJdATP (1000Cl/mmolj Amersham, Arlington
Helqhts, IL, USA) and 21l( of Sequenase diluted 1:8 In enzyme dilution butter,
and Incubated at room temperature for 5 minutes. Termination reactions
were initiated when 3.5f.11 of the lelbelling reaction was added to each of four
tubes containing 2.5111 of one of the four dldeoxynucleotide trlphophates
(ddATP, ddCTP, dclGTP or ddTIP), and Incubated at 37°C for 3 minutes.
Four III of stop solution was added to each reaction. Prior to loading,
samples were heated to 100°C and placed on Ice.
Gel-Mix 8 (Life Technologies, Gaithersburg, MD, USA) was used to prepare
sequencing 9F)(S. Gels were run at SOW in O.5X rBE (45rnM Tria-borate and
1mM !;DTA, pHS).
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2.13 Primers
All primers were synthesised by the Centre of BioTechnology at St. Jude
Ohlldrsn's Research Hospital, Mamphi$, TN, USA. Nucteotldes that were
altered tram the original sequence, so as to Introduce a rsstrlctlon site,
mutation or premature stop codon, are Indicated in lower case letters. A
short explanation of each primer is Included to make its origin clear. The
sequences of clones 7-8, 20A.~1j 5'·250A,-1 and TPR-MET in pGEM-9Zf(-) are
illustrated In figures ~.1. 2.2, 2.3 and 2.4, respectively, and their derivation Is
explained under plasmid construction ( see section 2.14).
2.13.1 peR primers
3'·A38 The reverse complement of the sequence found at positions 64~ 669
In clone 7..8 (5' G1TGTAGTCGGTCATGATGGTCGAGGT3').
_a'·L1C1 ~ The reverse complement of sequences at positions 1777-1818 in
clone 7-8 (5' CATA'rrCACGTGTCaagClTCCACGGCCGGCCCTCaAGGGAC 3'). A
Hindi" site and a stop codon were engineered.
,3'-t:\C42MOD Reverse complement of nuoleotldes at positions 2113-2157 in
7..8 In pBS (5' CAAGCCCTGTTGCTGGTAGCCaagcTTGACATTCCCtCAAGGGAA
3'). A Hindlll site and b; atop codon were engineered.
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3'END RV-1 Corresponds to nucteotldes at positions 1943·1969 in clone 7-8
(5' ATCCTATAGCAAAGAAGGAGCCACACG 3').
31END RV-2 Reverse complement of sequences at positions 2227·:::!261 in
clone 7·8 (5' GTGTGCGACCGAtaTCAGGGCCCAGGCTGGITCAT 3'). AnlEcoRV
site was engineered.
3'L~ Reverse complement of nuoleotldes at positions 1267u1290 In
clone 7·8 (5' CATGAAGGCCTCTGGGGGCATCC;~ 3').
3'METH·~ Reverse complement of sequences at posltlons 487·519 in clone
7..8 (5' ACCACACTICAACCTTAAGACCACTGGTGGTGT 3') .
.Q.'.:.&).S& Polylinker of p81uescrlpt and 5' untranslated sequences at positions
9~1·124in clone 5'-250",-1 (5' TAGTGGATCCCCCG'~ 3CGCCliCTCT 3').
fi.::.~ Nucleotldes at positions 1885..1920 in clone 7..8 (5' AGCTTGTGG
AACCCAACGTACGGCTCCTGGTITACA 3').
~~C154(±.l Sequences at posltlons 1438-'1460 in clone 7..8 (5'
AAGAACTGCCOTGGGCCTGTATA 3').
B'END RV_:1Nucleotldes at poslrlous 159 ..194 11"1clone 7-8 (5'
TATCCcCGggCGCC1TOTCTCCTACCTAAGTGCGTG 3'). A Smal site was
engineered.
B'(~ND RY·~Aeverse complement of sequences at positions 531 ..f554 In clone
7..1~(5' ACTAAGTGCTGTCCAOTAATATGC 3').
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p'Ly.s ..60 Nucleotldes at positions 784-843 in clone 7-8 (5'
CAGGTGTCCGGAATGCC',cMCGACCCAAGCCCCCTGCMGTGGCTGTC1AgGACGCTG
CCT 3'). The lysine at amino acid position 210 was mutated to an arginine.
~'METI-!·J;;..QNucleotides at positions 181-240 in clone 7-8 (5'
TACCgAAfTr.CGTGCCCCCACCCGATGGMGATICGdfGGACcTGGACc1·GAGCCCCC
TG 3'). In addition to engineering an EooRI site, the methionines at amino
acid positions 5, '/' and 9 were f'I1utstcd to leuclnes.
AS-3'A~ Reverse complement of sequences at positions 763·789 In clone
7·8 (5'CACCTGGCCITCATACACCTCCCCAAA 3').
f\..§;:3'MET-A..E..~Reverse complement of nucleotldes at positions 925·956 in
TPR~METin pGEM..9Zf(~)(5' CCTCTTCCTATGACrrCA TTGAAATGCACAAT 3').
A,S..3'UT-MET-tl3-SAU Reverse complement of untranslated sequences at
positions 1863..1905 in TPR-MET in pGEM-9ZfH (5' CAAAGTGTCGACTGAA
GCTITGACATAGTACTAGCACTATGAT 3'). Both a San and a Hlndlll site were
introduced into the primer.
A.S.;~KPT·NPM~METThe reverse complement of nucleottdes from the portion
of NPM Immediately 5' of the breakpoint, and the region of MET lrnmedlately
3' of the fusion junction. The itallslsed nucleondes are derived from NPM' ~t
positions 536M556 (clone 7..8) while the other nuoleotldes are from MET at
positions 725"745 crPR-MIET In pGEM-9Zf(--}) (5'
GAGATGAAITAGC.AAACTGAT C1flCTAAGTGCTGTCCAOTAA 3').
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~g The reverse complement of A3e~S(5' ATGCACTGGCCCTGAACC
ACATGCCTCTGCTTCAACAATGTG3'),
A38-S The nucleotldes at positions 376~396 and 514-534 in elorle 7-8
(5'CACATTGTrGAAGCAGAGGCATGTGGTTCAGGGCCAGTGCAr3').
~MI2.:§.The reverse complement of t.MS-C (5' CTrCCGGCGGTACACTACT
AAC'ITCAACCTIMGACCACTGG 3')
AMS-C Sequences at positions 493-513 and 550-570 "'. clone '('..8 (5'
CCAGTGGTCTrAAGGTTGMGTIAGTAGTGTACCGCCG'3AAG3').
S-3'MET-RV Nucleotldes at positions 1688-'j 717 in "(PO-MET in pGEM-97.fH
(5' CTGAACTGGTGTCClJGGATATCAGCGAT0T3'),
S-5'UT-NPM-H3 Untranslated sequences at positions 163-189 In clone 7..8
(5' TCCGTCaagC·(TCTCTCC1·ACCTAAGT 3'). A Hind'" site was engineered,
S-5'\JT-TPJ3:SMAIUntransJated sequences at positions 254-285 In TPR..MET
in pGEM-9Zf(-) (5' CTACCCCGg'~GCCCGCTGCCACTGGGTCCCT3'). A Smal site
was engineered.
~-BKPT·T..E.R-ALKNuoleotldes from the portlon of TPR Imme.dlah;ly 15'01 .na
breakpoint, and tile region of ALK Immediately S' of the fusion junctlcn, The
ltallslsed sequences are derived from TPA at positions 704·'/24 (.,...t'R·ME:T in
pGEM-9Zf(-)), whereas the other nuoleotldes are from Ai.I' at posltlons
557-571 (clone 7·S) (5' AAGAACrTGAATAGTTAACAG
TGTACCGCCGOAAGCACCAGG3').
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S..D64-NPM Sequences from positions 175·204 in clone 7·8 (5' CTCTC0TAC
CTAcccGgGTGCCCCCACCCGATGAATTACGMGGCAGTCGAATIAAAGTA 3'). A
Smal site was engineered.
2.13.2 ~\equencing primers
J\S ..ALK:g5, Reverse complement of sequences at positions 865·878 in clone
7-8 (5' AGGAAATCCAGTTCGT('CTGITCA 3').
AS-KR-21 Reverse complement of nucleotldes at positions 995-1015 In clone
7-8 (5' TCTCTCGGAGGAAGGACTTGA 3').
A§::MS,Ijl01-922 Reverse complement of sequences at positions 986-1007
in TPR·METln pGEMu9Zf(-) (5' TTCTTGCCATCATTGTCCAACA 3').
AS-ML-~ Reverse complement of sequences at positions 607-629 in clone
7-8 (5' TIGCTCAGCTTGTACTCAGGGCT 3').
pJ3_G:TPB Reverse complement of nucleotldas at positions 232·257 in TPH-
METin pGEM-9ZfH (5' GTAGAAGCGGAGAAGMI.'\GGCGAAGA 3').
~E.=X-N_EM. Reverse complement of sequences at positions 376·396 111clone
7·8 (5' TGCCrCTGOTTCAACAATGTG 3').
pQF..:MRM::[, Sequences at positions 405-432 in clone 7·8 (6' CGAAGGOAG
TOOM TTAAAGTAAOACTG 3').
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pUC MiS REVERSE In the polyllnker of pBluescript at positions 3-21 In clone
7-8 (5' GGAA.,ACAGCTATGACCATG 3').
S-3'MET Nucleot!des at positions 1586-1616 in TPR..MET in pGEM-9Zf(-) (5'
TGCAAGGGAGAAGACTCCTACAA(;CCGAATA 3').
~-AC-~ Nucleotides at position 1378·1401 in clone 7-8 (5' AGCAAAAGC
AACCAGGtlj'\GlT'CTG 3')
S-KR-22 sequence at positions 668-689 in clone 7..8 (5' ACTACTGCmGCT
GGCAAGAC 3').
S-MB-23 Sequence at positions 392-414 In clone 7-8 (5' AGGCAATGAATT
ACGAAGGCAGT 3').
Sp.§ Sequence at positions 23-41 in TPR..M£Tin pGEM-9Zf(-) (51 GATlTAGG
TGACACTATAG 3').
IIThe reverse complement of nucleotldes at positions ~u96-2115 in TPR..
MET In pGEM-9Zf( ..) and positions 2638-2657 in clone 7..8 In (5'
TAATACGACTCACTATAGGG 3').
·rPR-3' Nucleotldes at positions 619-641 In TPR"MET in ~GEM-9ZfH (51
GCCA1TCAGAGCCAAnTACAAG 3').
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2.14 Plasmid construction
t:JPM-ALK:_Clono 7-8 is the NPM·ALK cDNA with its 5' and S' untranslated
(UT) ends cloned Into the cooRI site of pBluescript SK(+} (Stratagene, La
Jolla, CA, USA) (figure 2.1). Since one of the EooRI sites was destroyed
during cloning, the 2.4kb NPM-ALK cDNA was excised from clone 7·8 using
SmailEcoRV to yield template for PCRs. The 5'UT and S'uT ends of clone 7·
8 were trimmed prior to cloning into the retroviral vector pSRa.MSVtkneo
(provided by Owen Witte, HHMI, University of California, Los Angeles, CA,
USA) (Muller et al, 1991). All of the S'UT end was trimmed, by engineering
an cooRV site, using peR primers S'END RV·1 and S'END RV-2, and the
2.4kb NPM-ALK eDNA as template. The resulting 319bp PCR product which
corresponds to the nucleotldes encoding amino acids 580-680 of NPM ..ALK
and 16bp of S'UT sequence, was digested with BstEll/EcoRV to yield a
273bp fragment. S!:'I"ilarly, ('!one·7-8 Was digested with BstEII/EcoRV to
release a 610bp insert, which was replaced with the 273bp fragment. The
resulting construct was designated 20,",,1 (figure 2.2). The S'UT end was
pruned by engineering a Smal site Immediately 5' of the Kozak sequence
using peR primers 5'END RV~1and G'ENDRV-2, and the 2.4kb NPM-ALI(
cDNA as template. The 396bp PCR fragment which corresponds to the
36bp Immediately upstream vf the start codon and the nucleotldes
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NNGGAAACAGCTATGACCJ.TGATTACGCf,illAGCTCGAAATTAACCCTCACTAAAGGGAAC 60
AAAAGCTGGAG~~CGGTGGCG~CCGCTCXAGAACTAGTGGATCCCCCGG~CTGC 120
AGGAATTCCGGCGGTTGTTCTGTGGAGCAGCGTTCTTTTATCTCCGTCCGCCTTC'~CTCC 180
TACCTAAGTGCGTGCCCCCAC('C_<jATGGAAGATTCGA~'GGAC,1l.TGGACATGAGCCCCCTG 240
AGGCCCCAGIl.!ACTATC'l'TTT .."GTTGTGMC'l'MAGGCCGACAAAGATTATCACTTTAAG 3 00
GTGGATM.TGATGAAAATGM1CACCAGTTATC'.t'TTM.GAACGGTCAGTTTAGGGGCTGG'l' :160
GCAMGGATGAGTTGCACATTG'I'TGAAGCAGAGGCMTGAATT.ACGAAGGCl'.GTt:CMTT 420
AAAG'rAACACTGGCMCTTIJ.'GMl\ATGTCTGTACAG::CMCGGIJ:''.t'TCCCTTGGGGGC'VTT 480
GAAATMCACCACCAG'l'GGTCT.'l'AAGGTTGMG'I'GTGGTTCAGGGCCAG'l'GCA.TA'lJTAQ'l' 540
GGACAOCACTTAGTAGffiTACC:~CCGGAAGCACCAGGAGCTGCAAGCCATGCAGATGG->:: 600
CTGCAGAGCCCTGAGTACAAOCTGAGCAAGCTCCGCACC'I'CGACCATCATGACCGACTAC 660
MCCCCAACTACTGC'J.'TTGCTGGCAAGACCTCCTCCATCAG'l'ciACCTGAAG9AGGTGCCG 720
CGGAAAAACATCACCCTCATTCGC~GGTCTGGGCCATGGCGCCTTTGGGGAGllTGTA'rGM 780
GGCCAGGTGTCCGGAATGCCCAACGACCCAAGCCCCCTGCAAG'l'GGCTGTGAAGACGCTG 840
CC'I'GMG'l'GTGCTCTGAACAGGACOAACTGGATTTCC'l'CATGGA.'",GCCtTGATCATCA(~C 900
AAAT'I'CMCCACCAGMCATTGTTCGCTGCATTGGGGTGAGCC'J)GCMTCCCTGCCCCGG 960
lJ.'TCJ~.'l'CCTGCTGGAGCTCA'l'GGCGGGGGGAGACCTCAAGTCCTTCCTCCm~'1. ~G.ACCCGC 1020
CC'l'CGC(~CGAGCCAGCCCTCCTCCCTGGCCATGCTGGACCTTCTGCACGTGr1!.'!~CGGGAC 1080
~.T'1'GCCTG1'GGCTGTCAGTATTTGGAGGAlUiACCACTTCM f CACCGAGACA1\~(-iCTGCC 1140
AGMAC'1'GCC'rCTTGACCTG'l'CCAGG'=CCTGGAAGAGTGGCCAAGATTGGAGACTTCGGG 1200
ATGGCCCGAGACATC~~CAGGGCGAGCTACTATAGAAAGGGAGGCTGTGCCATG(~TGCCA 1260
GTTAAbTGGI4.'l'GCCC(CCAGAGGCCTTCA'l'~ ,iliGGMTA'l''l'CACTTCTAAMCAGACACA 1320
'l'GGTCCTTT~GAGTG¢ ..(!,dC'l'A'l'GGGMATCT'l"l'TCTCTTGGATATATGCCj>''l'ACCCCAfilC 1380
IAAAAGCMCCAGGMG'.t'TCTGGAGTT'l'GTCACCAGTGGAGGCCGGATGGACCCACCCAJI.~ 1440MCTGCCCTGGGCCTGTATACCGGATAA~rGACTCAGTGCTGGCAACATCAGCCTGAAGAC 1500
AG(aCCCAAC'rT'.t'GCCA';r;lCATTT'l'GGAGAGGATTGAATACTGCACCCAGGACCCGGAT~';;TA 1560
ATCMCACCGC'l'TTGCCGATAGMrL'ATGGTq(~ACTtl'GTGGMGAGGMGAGAAAGTGCCT 1620
GIJ.'GAGGCCCMGGACCCTGAGGGGGT'1"CC'll,C'l'C'l'CCTGGTCTCTCAACAGGCAAMeGG 1680
GAGGAG~AGCGCAGCCCAGCTGCCCCACCACCTC'l'GCC'l'ACCACCTCCTCTGGCAAGGCT 1740
GCAAAGA&~CCCACAGCTGCAGAGGTCTCTGTTCGAGTCCCTAGAGGGCCGGCCGTGOAA 1800
~GGGACACGTG~ATATGGCATTCTCTCAGTCCAACCCTCCTTCGGAGTTGCACAAGGTe 1860
tACGGATCCAGAAACAAGCCCACCAGCTTGTGGA~CCCAACG~ACGGCTCCTGGTTTACA 1920
GAGAAACCCACCAAAAAGAATAATCCTATAGCAAAGAAGGAGCCACACGACAGGGGT~C 1980
CTGGGQCTGGAGGGMGCt.l.'G'l'ACTGTCCCACCTAACGTTGCMCTGGGAGACTtJ.'CCGGGG 2040
GCCTCACTGCTCCTAGAGCCC'l'C'l'TCGCTGAC'l'GCCAM,'A'l'GMGGAGGTACC'l'C,('GTTC 2100
AGGCTACGTCACTf\CCC'l'TG',rt3GGAATGTCAAT'l'ACGGCTACCAGCJ.ACAGGGC'l'TGCCC 2160
TTAGAAGCCGCTA6TGCCCCTGGAGCTq~~~~t!~PGAQQb~~eATTCTG~AAG 2220
AA.TAGCATGAA£,ql\.~C~Ci9.2SJTGAGC~~CGGTCGCACACTCACTTCTCTTCCTTGGGA 2280
TCCCTAAGACCGTGGAGGAGAGAGAGGCAATGGCTCCTTCACAAACCAGAGACCAAATGT 2340
CACGTTT .:'GT'l'T'l'GTGCCAACCTATTTTGAAGTACCACCAAAAAAGCTGTATTTTGMM 2400
'l'GCT'l'TAGAAAGG'I'TTTGAGCATGGGTTCM'CCTATTCT'l''l'CGAAAGAAGAAAATATCAT 2460
AJIAAATGAG'l'GAT]i,J.\ATACAl\GGCCCAGA'l'GTGGT'J'GCA'J:iMGGTTTTTATGCATGTTTG 2520
TTGTATACT'l'CCTrJ,'ATGCT'l'CTT'l'TAA1HTGTGTGTGCTC'~":1CTTCAATCTAGCCGGAAT :25 8 0
TCGATATCAAGCTTATCf&AT~~~9~~A~CT~AGGGGGGGCCCGGTACCCAATTCGccc 2640
TA'l'AGTGAGTCGTAT'I'AG_ :2 658
Figure 2.1. Clore 7-8. This clone Is tile N'"'M·ALK eDNA with its 5' and 3'
untranslated ends cloned Into the IEcoRI site of p81uescript SK{+). Tile
shaded area represents ,he coding sequence; underlined sequences
correspond with p81uesorlpt polynnker; and remaining eequenoes are the 5'
and 3' untranslated ends. (Genbank accession number HSU04946).
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NNGGAAACAGCTATGACCATGATTACGCCAAGCTCGAAATTAACCCTCACTAAAGGGAAC 60
8~AAGCTGGAGCTCCACCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGC 120
AGGAATTCCGGCGGTTGTTCTGTGGAGCAGCGTTCTTTTATCTCCGTCCGCCTTCTCTCC 180
TACC~TGCGT""CCC<;l'CCCgATGGM. ..GATiCdA.TGGACATC.'GACATGAGCCCC.t":T..GI 240
AGGCCCC.l\.GAACTA'l'CTTTTCGGT'l'GTGMC'1',AM.GGCCGACMAGATTATCACTT'I'MG 300
I.';TGGA'l'AATGATG~.AATGAGCACCAG'tTATCT'ltTMGAACGGTCAGTTTAOGGGCTGGT :':160
~Ct.MGG1~TGAGTTGCACATTGTTGMGCAGAGGCM.TGAA'l'TACGAAGGCAGTCCAATT 420
AAAGTAACACTGGCAAC'l'TTG~~TGTCTGTACAG~CAACGGTTTCCCT~GGGGGCTTT 480
(lAMTAtl.CACCACCAGTGG'rCT'l'AAGGTTGAAG'X'GTGG'I"l'CAGGGCCAG'l'GCATATTAGT 540
G~ACAC:lC~q~TAGTAG2PTACCGCCGGMGCACCAGGAGCTGCAAGCCA'l'GCAGATGGAG 600
d~GCAGA ,~JCTGAG'ltACAAGCTG.·AGCAAGCTCCGCACCTCGACCATCA'l'G.1tCCGAC'l'AC 660
M\tJCCCAAC'l'ACTGC'l''l'TGC'l'GGCAAGACC'l'CC'l'CCATCAG'l'GACC'rGAAGGAGGTGCGG 720
CGGAAAAACATCACCCTCAT'rCGGGGTC'l'GGGCCA'l'GGCGCCTTTGGGGAGGTG'l'~.TGM 780
GGCCAGGT~TCCGGAA'l'GCCCAACGACCCAAGCCCCC'l'GCAAGTGGCTGTGAAGACGCTG 840
CCTG1!JI"G~G'rGCTC'l'GAACAGGACGAACTGGATTTCCTCATGGMGCCCTGA'l.'CJl.TCAGC 900
AMTTCMCCACCIIGAACAT'l'GTTCGC'l'GCATTGGGGTGAGCCTGCMTCCC'1'GC'CCCGG 960
'!'TCATj;!C'l'GCTGGAGC'l'CATGGCGGGGGGAGACCTCAAGTCCT'l'CC'L'CCGAGAGACC~GC 1020
cCTCCfCCCGAGCCAGCCCTCCTCt'~CTGGCCATGcrI'GGACC'l'T(;TGCACG,!'GGC'l'CGGGAC 1080
l\'l''l'GCCTG'J,'GOC'l'GTCAGTAT'l'TGGAGGAMACCACTTCATCC1\.CCGAGACATTt:;CTGCC 1140
AGAAAC'.l'GCCTC'l'TGACCTGTCCAGGCCCTGGAAGAG'l'GGCCMGA'l'TGGAGACTTCGOG 1200
J:.TGGCQCGAGACATCTACAGGGCGAGC'l'ACTATAGAAAGGGAGGC'}1GTGC(:ATGC'l'GCCA 1260
GT'l'MGTGGATGCCCCCAGA(~GCC'l''l'CATGGAAGGMTATTCAC'l:±CTAMACAGAC)l.OA 1320
iJ.'GGTccil'l'TGGAGTGCTGC'l'ATGGGAAA'l'CtL';t''l'TCTCTT'jGATAT A'L'CKtCATACCCCAGC 1380
AAAAGCi'..ACCAGGMGT~CTGGAGTTTGTCACCAGTGGAGGCCGG,tl.TGaAceC.ACCCAAG 1440
MCTGCCCTGClGCC'l'G'l'ATACCGGA'l'AA'l'GACTCAGTGCTGGCMCA 'l'CAGCCTGMGAC 1500
AGGCCC;MCTTTGCCNl'CA'l'TTTGGAGAGGA'l'TGAATACTGCACCCAGGACCCGGATGTA 1560
ATCAl\,~~ACCGC'l'~'TGCC'3ATAGM'l,IATGG'l'CCACT'l'G'l'GGAAGAGGAAGAGMAGTGCCT 1620
G'l'GAG(JCCCMGGACCC'I'GAGG(;GGT'l'CC'l'CCTCTCCTGGTCTC',liCMCAGGCAll..MCGG 1680
GAGGAGGAGC(;CAGCCCAGCTGCCCCACCACCTCTGCCTACCACCTCCTCTGGCMGGCT 1740
GCAAAGAAACCCACAGC'l'GCAGAGGTC'l'C'l'GT'l'CGAGTCCCTAGAGGGCC~OCCGTGGAA 1800
GGGGGACACG'l'GAATATGGCATTCTC'l'QAGTCCAACCC'l'CCT'l'CGGAGTTGCACAAGJTC 1860
CACGGATCCAGAAAqAAGCCC ACCAGC'X'TG'l'GGMCCC).l.ACGTACGGC'l'CC'l'GGTT'rACA 1920
GAGAAACCCACcMAAAGMTAA'l'CC'l'.~TAGCMAGMGGAGCCACACGACAGGGG'l'MC 1980
CTGGGQCTGG~GGG1MGC'l'GTAC'l'GTCCCACC'l'.I1.ACGTTGCMCTGGGAGAC'l"rCCGGGG 2040
GCCTCACTGC'l'C~TAGAOCCCTCT'l'CGCTGACTGCCAATATGAAGGAGGTACC'l'CTOTTC 2100
AGGC'.I'ACG'l'CACT'l'CCC'.t''l'GTGGGAATGTCAAT'I'ACGGCTACCAGCAACAGGGC'I''l'GCCC 2160
TTAGAAGCCGCTACTGCCCCTGGAGC'l'GGTCA'I'TACGAGGA'I'ACCATTCTG~GCAAG 2220
A,tt,tAGCA'l.'GMCCAG££'l'GGg,CCsJ'I'GA'I'~GCT:TA'l'CGA~~"CGTCGACCTCGM§§. 2280
GGGGC~cq~~cCCAA'l'yCGCCcT~t~GTGAG'I'CGTATTAC 2321
F!gur~ 2.2. Clone 201.-1. rhe 3' untranslated sequence from clone 7·8 was
trlmmsd. The Shaded area represents the coding sequence; underlined
sequences correspond with pBluoscrlpt polylinker; and remaining sequences
are the 5' and 3' untranslated ends.
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encoding the first 117 amino aclds of NPM-ALK, was digested with
Smal/Aflll to produce a 334bp h;agment. Clone 20",~1 was also digested
with Smal/AfIIl to liberate a 388bp insert, which was substituted with the
334bp fragment. This construct which was termed 5'-250", ..1 (figure 2.3),
was digested with SmaiIEcoRV, and Hindi II linkers (New England BloLabs,
Beverly, MA, USA) were added. This 2083bp insert was subsequently cloned
into the HindU I site of pSRexMSVtkneo (prepared by Mark Kirstein in the
laboratory of S.W. Morris).
1PR-MET: A 1.99kb EcoRI TPR-MF.T insert with Its S'UT and 3'UT ends
(provided by Morag Park, McGill University, Montreal, Canada) was cloned
into the ceoRI site of pSRaMSVtkneo. The 1.99kb insert was used as
template for peRs.
TPR-ALK: This chimaera was generated using both tlhe 2.4kb NPM ..AL/( and
1.99kbTPR ..METcDNAs as templates, and peR primers s-S'Ur ..TPR..SMAI, S..
BKPr"TPR-AL.K and AS-3' ..ALK. The 703bp F0R product which encompasses
44bp of S'UT sequence and the nucleotides encoding the entire coding
region of theTPR portion inTPR..ME'T and the nucleotides encoding amino
acids 118-195 of NPM-ALK, was digested with Small Nan to yield a 665bp
fragment. The Smal/Nan digestion of clone 20A,,,1released a 645bp Insert
which was replaced with the 665bp fragment. This construct was
sequenced using primers pUC M13 REVERSE, pBS-TPR, TPR·3' and
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.ill?AA..l\.CAGCT~aCCATGATTACGCCAAGCTCGA1'I.AT'IAACCCT(,.AC'l'AAAGG(JMCM 60
~GCTGGAGC~CCACCGCGGTGGCGGCCGCTCTAGMCTAG~GGATCCCCCGG~CGCCTT 120
CT(!TCCTACCll'AAQ.~ITGCCS:CCACCC_gATGGMGATTCGATGGACATGGACATCAGC 180
CCCC'l'GAGGC'.PCCAGMCTA'l'CTT'I'TCGGT'l'G'I'GMCTAM.GGCCGACAAAGATTA7'CAC 240
TTTMGGTGG:i{TAATGM'GAAAATGAGCACCAGTTATCTT'l'Al'\.tl.MCGGTCAGT'lli'AGGG 300
GCTGG'I'GCAAAGGA'l'GAG'I'TGCACATTGTTGAAGCAGAGGCAA'r'GAATTACGl4r,QGCAGT 360
CCM'1'TAMGTAACAC'l'GGCAAC'l'T'l'GAAAA':'G'1'CTG'l'AC.MCCMCC';GT'I''I'CCCTTGGC 420
GGC'l''l''I'GAAATMflACCACCAGTGG'.ItC'l'II'MGGT'.%lAAGTGTIJGTTCAGGGCCAG'l'GCA';r.' 480
AT'!'AGTGGACAGCAC'l''l'AGTAGjf.3TACCGCCGGl',.(I.GCACCAGGAGC'l'GCAAGC.,,;)ATGCAG 540
A!rGGAGCTGCAQ.l\.OCCCTGAG'l']!.CAAGcrl'GAGc..:.AAGCTCC~,zACCTCGACCNl'CATGACC 600
GACTACMCCCCAAC'l'AC'l'GC'l'TTGCTGGCAAGACCT.CC'l'CCA'I'CAG'I'GAC'C'.l:'GMGGAG 660
G'l'GCCGCG(~AAM~CA'I'CACCCTCA'l''I'CGGGG'l'C'l'GGGCCATGGCGCc'l''l'TGGGGAGG'l'G 720
TA'l'GMGGCCAGG'J.'O'l'CCGGAATGCCCAACGACCCAAGCCCCCTGCAAGTGGC'l.'G'l'GMG 780
ACGCTGCC'l'GA?-.G'l'GTGC'l'C'l'GMCAGGACGMC'l'GGA'I'TTCC'l'CA'l'GGAAGCCCTGATC 840
ATCAGCMA'l'TCMCCACCAGMCA'l''l'GT'L'CGC'l'GCATTGGGGrl'GAC:itCTGCAA'l'CCC'.l'G 900
CCCCGGT'l'CATCC'!'GCTGGAGC'l'CA'l'GGCGGGGGGAGACC'l'CMGTCC'l"I'CCTCCGAGAG 960
ACCCGCCC'l'CGCCCGAGCCAGCcctrCCTCCCTGGCCA'l'GCTGGACC'l''l'CTGCACGTGGC'1" 1 0 2 0
CGGGACA'l''l'GCCTG'J'GGCTG'l'CAG'l',l\.rl''l'TGc.~AGGA.l\AACCAC'l''l'CA'l'CCACCGAGACA'!'T 1080
GCTGCCAGAAAC'l'GCCTCTTGACCTGTCCAGGCCCTGGAAGAG'l'(;GCCAAGA'l''l'GGAGAC 1140
T'l'CGGGA'l'GGI..'!CCGAGACATC'l'h.CAGGG.tGAGCTACTATAGAMGGGAGGC'l'G'l'GCCATG 1200
C'VGCCAGTTA..~GTGGA'l'GCCCCCAGAGGCCTTCATGGMGGAA'l'A'l'TCP.C'l'TCTA1\AACJ.I. 1260
GACACATGGTCC1''J.''l'GGAGTGC'l'GCTA':t'GGGAAATC'l'TT'I'C'l'CTTGGATATATGCCA'l'AC 1320
CCCAGC.MAAIZ.C.A.ACCAGGAAG'l'TCTGGAG'l'TTGTCACCAG'l'GGAGGCCGGM'GGACCCA 1380
CCCAAGAAC'l'';';CCC'L'GGGCC'l'G'l'AT.ACCGGATMTGAC'l'CAG'l'GC'l'GGCA1~CA'l'CAGCC'!' 1440
GAAG.n..t.:AGGC(.'CAAC'l'TTGCCA'l'CA'l'TTTGGAGAGGATTGAATl\(.'!TGCACCCAGGACCCG 1500
GATG'l'~\TC~CACCGCTTTGCCGATAGAATATGG'l'CCACTTGT~GAAGAGGAAGAGAAA 1560
GTGCCTG'l'GAGGCCCMGGACCC'l'GAGGGGGTTCC'l'CCTCTCC'l'OGTC'l'CTCAACAGGCA 1620
AMCGGGAGGAGGAGCGCAGC'cCAGCTGCCCCACCACCTC'l'GCC'l'ACCACC'.('CCTC'l'GGC 1680
AAGGC'I'GCAAAGAAACCCACAGC'I'c1CAGAGGTC'l'C'l'G'l'TCGAG'l'CCCTAGAGGGCCGGCC 1740
G'l'GGMGGGGQACACGTGAA'I'A'l'GGCA'l"l'CTC'.['CAGTCCAACCCTCC'l''!'CGGAO'l'TGCAC 1 BOO
AAGG'1'CCACGGA'l'CC.MAMCAAGCCCACCAGCTTGTGGMCCCAACGTACGGCTCCTGG 1860
·V'l'l'ACAGAGAMCCCACCAAMAGM'l'AATCC'l'A'l'AGCA.AAGMGGAGCCACACGACAGG 1920
~
T~\CCTGGGGCTGGAGGGAAGCTGTAC'l'GTCCCACCTAACG'l'TGCAACTGGGAOACTT 1980
CGGGGGCCTCACTGCTCC'l'AGAGCCC'l'C'l'TCGC'l'GACTGCCAA'I'A'l'GMGGAGGTACCT 20~0
'l'G'l'TCAGGC'l'ACGTCAC'l''l'CCCTTG'l'GGGMTG'l'CAATTACGGC~ACCAGCAACAGGOC 2100
TGCCCTTAGMGCCGCTACTGCCCCTGGAGCTGG'l'CAT'l'ACGAGGA'l'ACC~TTCTGAAP. 2160
GCAAGAATAGCATGA1I.CC1).GCCTGGG9.£f'trGATATCAAGC'l'TATCGA'T'ACCGTCGACCT 2220
~GGGGGGGCCCGGTACCCAATTC~~TGAGTCG~TTAC 2267
Figure 2.3. Clone 5' 250/.....1. Most of the 5' unteanslatsd end was removed
from clone 20A.e1. The shaded area represents the coding sequence;
underlined sequences correspond wltn pBluescript polylinker; and remaining
sequences are the 5' and 3' untlianslated ends.
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AS-ALK..24. The 2155bp TPR~ALI(was excised with SmallEooRV, EooRI
linkers (New England BioLabs, Beverly, MA, USA) were added, and the
chlmasrlc construct ligated into the S'ooRI site of pSRcxMSVtkneo.
fjPM-MET: The 1.99kb EcoRI TPR-ME'f cDNA insert was cloned Into the EooRI
site of plasmid vector pGEM-9Zf(-) (Promega, Madison, WI, USA) (figure
2.4). To generate an NPM-MET chimaera with the 5'UT end trimmed, the
same DNA templates were utlllsed as for the construction of TPR-AU(,
together with PCR primers SM5'UT-NPM-H3,AS..8KPT-NPM-MET and AS-3'-
MET-APAI. The 626bp PCR :ragrnent which corresponds to 42bp of 5'UT
sequence and the nucleotldss encoding the entire coding region of the NPM
portion In NPM..ALK and the nuoJeotldesencoding smlno acids 143-220 of
TPR-M£T; was out with HindllllApal to yield a 557bp fragment. tPR-MET in
pGEM-9Zf(-) was digested with HlndllllApal to liberate an 856bp insert
which was replaced with the 557bp fragment (designated clone 626). Clone
626V"as sequenced using primers SP6, pGEX-NPM, pQE-NPM-3' and AS-MET-
901..922. To trim the 3'UT end, the 1.99kb TPA..MEr cDNA template and
peR primers Su3'MET..RV and AS-3'UT-MET-H3·SALI were used. The resulting
2'I8bp peR product which encompasses the nucleotldes encoding amino
aolds 464..523 of TPR..MET and 39 nucleotldas of S'UT sequence, was
digested with ecoRV/Sa/l to yield a 188bp fragment. Clone 626 was
digestRd with EooRV/Sall to release S79bp, which was substituted with the
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~CGACTTGGTCAGCGGCCGCAGATTTAGGTGACAC~~~TATGCATCACT~~ 60
CTTTGCTCTAGACTGGAATTCCGGCGGGGCGGTGAGGTGCTGTTGCTGAAACTGGCCGCT 120
GAGGGTGGACTCGATTTCCCAGGG'.I'CGCCGCGGGAGTCTCCGGCGGGCGGGCGTGTGCGA 180
GCCACCGAGCGAGGTGATAGAGGCGGCGGCCCAGGCGTCTGGTCCTGCTGGTCTTCGCCT 240
TTCTTCTCCGC'l'TCTACCCCGT~GGCCGC'l'Gr.CACTGGGG'l'CCCTGGCCCCACCGA ATG 300
GCC;GCGC~TGTTGCAG(!AAGIL'caJ:iGAGCGCACGGhGCTGMCAAGCTGCCCAAC~TCTGTC 360
CAGAACAAACTTGAAAAGTTCCTTGCTGATCGGCAA'.t'CCGAGATCGA':"GGCCTGAAGGGG ,20
CGGCA,!,GJ'.GAAA'I',!'J.'AAGGTGGAGAG~~GMCAACAGTATTTTGAAA{~~GAAAAGAGGTTG 480
TCCCACAGTCA~GAGAGACTTGTGAATGAAACCCGAGAGTOTCAAAGCTTGCGGCTTGAG 540
CTAGAGAAAC'l'CAACM'l'CAACTGMG'':;CACTAP.CTGAGMAAACAAAGAAC'l'TGAAATT 6 0 0
GCTCAGG,IVl'CGCAATATTGCCATTCAGMCCA;i\.TTTACAAGAACAAAGGAAGAA'J.'TAGAA 660
'lSCTGAGMAAG:'!\.GACTTAA'!'TAGAACCM'I'(tAGAGACTA'X'CTCAAGAACTTG1.ATACT'1'A 720
AC~ATCAGTT'J.'CCTAATTCATCTCAGAJl.CGGTTCATGCCGACAAGTGCAGTATCCTC'l.!G 780
ACMlACATGTCCCCCATCCTAACTAGTGGGGACTCTGA'rA'L'ATCCAG'l1~CAJl'~~ACTGCAA 840
AATACTGTCCACATTGACC'!'CAGTGCTCTAAATCCAGAGCTGGTCCAGGCAGTGCAGCAT 900
GTAGTGATTGGGCCCAGTAGCCTGA'rTG'.I'GCATTTCAATGAAG'J.'CATAGGA AGAGGI..\CAT 960
TTTGGTTGTG'1'A'.rA'J:tC~.TGGGACTT'l'C;'l''1'GGACAATGA'1'GGCAAGAAM'.\.''.!.'CAC~l'G+GCT 1020
G'l'GAAATCCT'l'GAACAGM'!'CACtJ.lGACATAGGAGMGT'l'TCCf:MTTTCTGACCGtI.GGGA 1080
ATCATCATGAru'l\GA'l'TTTAGTCATCCCAATGTCCTC'l'CGC'l'Ce'!'GGGAA'l'CTGCC'l'GCGA 1140
AGTGMGGG'I'CTCCGC'!'GGTGC:iTCCTACCA'1'ACATGAAACATGGAGA'l'C'L'TCGAA1\TTTC 1:1 0 0
ATTCGAAA,!,GAGAC~P.ATAATCCAACTGTAAAAGATCTTATTGGCT'!'TGGTCTTCAAGTA 1260
(lfCAAAGGCATG,A.~lfrATCTTGC:AAGCAAAAAGTTTGTCCACAGAGACTTGGCTGCAAGA 1320
AACTGTATGCTdGll ...1.I1IAAAAATTCACAGTCMGGTTGCTGATT'r'I'GGTCTTGCCAGAGAC 1.380
ATG'I'ATGATAAAG&~TACTATAGT~'I'ACACAACAAAACAGGTGCAAAGCTGCCAGTOAAG 1440
TGGATGGCT'I'TGGAAAGTCTGCAMCTCMAAG'I'TT.l'I.CCAC'CAAGTCAGA'l'GTG'l'GG'rcc 1500
T':L'TGGCGTC(~TCC'I'CTGGG.l\.GCTGATGACMGAGGAGC:CCCACC'1''l'ATCCTGACGTAAAC 1560
ACCTTTGATATAACTGTTTACTTGTTGCAA~~GAGAAGACTCCTACAACCCGAATACTGC 1620
CCAC1ACCCCTTATATGAAGTAATGC'l'.AAMTGC'l'GGCACCC'J.'AAAGCCGA1I.A'!'GCaCCCA 1680
'l'CCTT'l''l'CTGAACTGG',!'GTCCCGGATATCAGCOATCTTCTCTACTTTCAT'!'GGGGA.GCAC 1740
TATG'!'CCATGTGAACGC'I'ACT'I'A'I'GTGAACGTAAAATG'I'G'1'CGC'I'CCGTATCCTTC'I'C'I'G 1800
'I".('GTCA'l'CAGM.GATMCGCTGATGA'l'GAGG'l'GOACll.CACGACCAGCCTCCTTC'l'GGGAG 1860
ACA C T~CTAGTACTA'rGTCAAAGCAACAGTCCACACTTTGTCCAATGGTTTTTTC 1920
ACTGCCTGACC'l"J!TAAMGGCCATCGATATTCTTTGCTCCTTGCCATAGG1-\CTTGTATTG 1980
TTATTTAAATTACTGGATTCTAAGGAATTTCTTATCTGACAGAGCATCAGAA.CCAGAGGC 2040
TTGOTCCCACAGGCCAGGGACCAATGCGCTGCAGGCCGGAATTCGTCGACGAGCTCCCTA 2100
TAGTGAGTCGTAT'r,AGAGGCCGACT'l'GGCq,-MA 2133
Figure 2.4. TPR..MET in pGEM-9ZfH. The TPR..MET cDI'IJAwith its 5' and 3'
untranelatec ends intact was cloned Into the cooRI site of pGEM-9Zf(-).The
Shaded area represents the coding sequence; underlined sequences
correspond with pBluescrlpt polylinker; and remaining sequences are the 5'
and 3' untranslated ends. (Genbank accession number HSU193413).
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188bp fragment. This construct was sequenced utilising primers S~3'ME"r
and T7. This 1549bp chlmaerlc construct Was digested with HindI!! and
subcloned into pSAaMSVtkneo.
':!_6/7/9NF?M-A:"'K: Methioninep. ct positions 5, '7 and 9 were mutated to
leucmes. The NI--'M-ALKeDNA was excised from pSRaMSVtkneoIIVPM-ALK
with Hindlll and cloned Into pBluescript SK(+) (clone pBS/NPM·ALK). peR
was performed using the 2.4kb NPM-ALK eDNA as tern plate with primer
pair 5'uMETH-60 and 3'-METH-33. The 339bp peR fragment which
corresponds to 24bp of S'UT sequence and the nucleotides encoding the
first i05 amino acids of NPM-ALK, was digested with E"coFlI/Aflll to produce
a 316bp fragment. Similarly, clone pBSINPM-AU( was digested with
EcoRIIAflll to liberate a 356bj) insert which was replaced with the 316bp
fragment. The construct was sequenced using the pUC M13 REVERSE and
ASuML ..23 primers. This 2.0S7bp mutant construct was cloned into the
EcoRlll-tlhdlll sites of pSRaMSVtkneo.
K210ANPM~AI:::f.<: The lysine residue at position 210 was mutated to an
arginine. peR primers 5'..LYS~60 and 3'-L YS-24, and the 2.4kb NPM..ALK
cDNA template were used to generate a 507bp product. This peR product
which corresponds to the nucleotldes encoding amino acids 194-362 of
NPM ..ALK, was digested with BspEIISful to yield a 492bp fragment. At the
same time clone 5'..250A-1 was dl'Jested with BspEllStul to liberate an
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insert of 492bp, which was substituted with the mutated 492bp fragment.
This construct was sequenced utilising primers S-KR-22 and AS-KR-21, The
2083bp mutant construct was subsequently cloned Into pSRexMSVtkneo
using the same procedure as for pSRexMSVtkneoINPM-ALK,
t.MBNPM·ALK: Amino acids 104 to '115 of NPM-ALK were deleted. Two PCR
reactions using the 2.4kb NPMMALK eDNA as template were set up in parallel
using primer pairs (1) 5'END RV..1 and AMB-B, and (2) AMB-C and AS-3-
ALK. The products of these reactions were used as templates for further
PCR using prima pair 5'END RV-1 and AS-3-ALK. The resulting 595bp
product which encompasses 36 nucleotldes of 5'UT sequence and the
nucleotides encoding amino aolda 1..195 of NPM-ALK, excluding the
nucleotides encoding the putative metal-binding region, was digested with
9maiiNan to give a 557bp fragment. This fragment was cloned into
SmaJINan-digested clone 20",..1 and sequenced using the pUC M13
REVEI=lSE,S-MS..23, pGEX-NPM and AS-AU(·24 primers. The 2G17bpmutant
construct was cloned Into pSRexMSVtkneo using the same procedure as tor
pSRexMSVtlmeoITPR-ALK.
A(J4NPM..ALK~ Amino acids ....64 were deleted from NPM-ALK. Utilizing the
2.4kb NPM-ALJ( cDNA as template and PCR primers S-D64..NPM and AS-3'-
ALK, yielded a 423bp fragment. This PCR fragment which encompasses
30bp of 5'Ur sequence and the nuclsotldes encoding amino acids 65-195 of
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NPM-ALK was digested with Sma/INar/ to yield a fragment of 377bp. The
377bp fragment was cloned into SmallNarl-dlgested clone 20A.-1 and
sequenced utilising primers pUC M13 REVERSE and AS-ALI<-24. The 1867bp
construct was subcloned Into pSRaMSVtkneo in the same manner as for
pSRaMSVtkneoITPR-ALK.
t:r.~5'1'J3NPM_ALI£ NPM amlno acids 65 to 103 were deleted. In the first round
of POR, two sets of reactions were performed using the 2.1kb XbailEcoRV
NPM-ALK eDNA insert from clone 5'..250A.-1, and primer pairs (1) 5'-A38
and LiSS-AS, and (2) .138-8 and 3' ·.138.The above peR reactions served as
templates for a second round of PCR using primers 5'..a38 and 3'-Li38. The
resulting 394bp product which corresponds to 52 nucleotldes of 5'UT
sequence and the nucleotides ~ncodlng amino acids 1-64 and 104-155 of
NF'M"AU(, was digested with SmallSlpl to yield a 340bp product. Clone 5'-
250A.-i was also digested with SmallBlpl to liberate a 457bp insert, which
was replaced with the 340bp fragment. This mutant was sequenced using
the pUC M13 REVERSE and AS-3'-AU< primers. The 1966bp deletion mutant
was ligated Into pSRaMSVtkneo as dssorlbed for pSAaMSVtkneol TPA-ALK.
t::.15!.;Ne.~U(: The 154 carboxy-terminal amino acids were deleted, and a
stop codon inserted. peR was performed with the 2.4kb NPM-ALK eDNA
template and peR primer pair 5'''AC154(+) and 3'a~C154 to yield a 381bp
product. The peR product which corresponds to the nuoleottdss encoding
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amino acids 412-538 of NPM-ALK, was digested with Bst11 0711Hindi II to
yield a 341bp product. Clone 5'..250",-1 was also digested with
Bst1107llHindlll to release a 794bp insert. which was replaced with the
341bp product. The construct was; sequenced utilising primers S-~C-24 and
T7. The 1634bp mutant construct W!~$ excised with SmallHINilll, Hindlll
linkers were added and the insert was subcloned into pSRaMSVtkneo.
2.15 Antisera
Anti-ALK #11 is a rabbit polyclonal antiserum directed aqalnst amino acid
residues 419,,520 '7;. ~PM-ALK (Morris et al., 1996). The murine monoclonal
antibody ALK-1 WEtS also prepared using NPM-ALK residues 419..520 as an
immunogen (Pulford at aI., 1996). Anti-MET rabbit polyclonal Ab143
(provided by Morag Park, McGill University, Montreal, Canada) recognises
amino acids 514-523 of TPR-MET, whereas the h-MET (0-28) antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) Is a rabbit polyolonel IgG
which recognises the 2,;3carboxy-terminal amino acids of the human c-MET
p140 ~ chain (Rodrigues et at, 1991). The antl-phosphotyrosine PY-20 is a
mouse IgG2b monoclonal antibody; the two SHO antibodies used al'e a
mouse monoclonal IgG1 entlbody, and a rabbit affInity purified polyclonal
antibody, both directed against amino acids 359~473 of the intact human
60
protein (Transduction Laboratories, Lexington, KY, USA). Anti-B23 is a
murine polyclonal antibody directed against the entire 38kD NPM (provided
by P.K. Chan, Baylor College of Medicine, Houston, TX. USA).
2.16 Immunofluorescence
COS- 7 cells were electroporated with the indicated DNA constructs and
grown on coverslips 24 to 36 hours prior to Immunostainlng. SUP~M2 and
K562 nells were cytospun onto glass slides. Cells were fixed with 4%
paretormaldehyde In PBS fOl.'15 minutes, washed twice with PBS and
permeabiHsed with 0.2% Triton X~100 in PBS for 10 minutes. The fl.<edcoils
were blocked In 5% dry milk in PBS for 30 minutes and subsequently
incubated with either monoclonal ALK·1 (neat) or h-MET (C28) (diluted
1:500) In PBS for 30 minutes. The cells were:washed six times with PBS ana.
then Incubated for 30 minutes with fluorescein (FITC)-conjugated donkey
antl ...rabbit or anti-mouse IgG (diluted 1:100) (Jackson lmmuno-Research,
West Gl'Ove, PA, USA). Follow!ng another six washes with PBS, the DNA was
counterstalrted with 1.51lg/ml of 4', t3..dlamldlne-z'ephenylindote
dihydrochloride (DAPI; Boehringer Mannnelm, indlanapolls, IN, USA) in PBS for
5 minutes. The ooversllps were mounted onto slides with Veotashleld
131
(Vector Laboratories, Burlingame, CAf USA) and examined under an
Olympus BX50 fluorescent microscope (Olympus, Japan).
2.17 In vitro transcription and translatton
In vitro transcription and translation was performed utilising the TNT
Coupled Rett~t~locyteLysate Systems (Promega, Madison, WI, USA) as per
package Instructions. The isotope utilised was L-[3SS]methlonlne
(1000Cl/mmol; Amersharn, Arlington Heights, IL, USA).
2.18 Immunoprecipitation
Cells were washed with PBS and lysed with Nonidet P-40 (NP-40) lysis buffer
(2SmM Trls-HOI, pH 7.5, 150mM NaCl, 1% NP-40, 44J.lg/ml aprodnln, 1.411M
phenylmethylsylfony! fluoride, 2mM ethylenedlamlne-tetraacetlc acid and
1mM sodium orthovanadate). Cell lysates were centrifuged and the
supernatants were incubated with the appropriate antiserum for 2 hours at
4°C, and immune complexes were collected on protein A-Sepharose CL·4B
beads (Pharmac+. Piscataway, NJ, USA) by incubation at 4°0 for one hour.
The beads were washed four times with NpN40 lysis buffer and resuspended
in 2X Laemmll sample buffer (62.5mM Trls-HOI, pH 6.8, 2% sodium dodeoyl
sulphate, 10% glycerol, 5% ~-marcapto€lthanol and a pinch of bromophenol
6:2
blue), boiled and subjected to reducing sodium dodecyl sulphate ~
polyacrylamide gel electrophoresis (SDS..PAGE) (Laemmll, 1970).
2.19 ImmunobloUing
Immunopreclpitates were prepared as described (see section 2.18),
resolved by SDS-PAGE and transferred to polyvinylldene difluoride (PVDF)
membranes (lmrnobllon..p; Millipore, Bedford, MA, USA) using a TE70
SemiPhor Transfer Unit (Hoefer Scientific Instruments, San Fransisco, CA,
USA) I. transfer buffer containing 48mM Trls, 39mM glycine, 0.037% sodium
dodecyl sulphate and 20% methanol. Membranes were blocked In 3% dry
milk in PBS for one hour at room temperature and incubated for a further
two hours with the appropriate antibody in blocking buffer. Following three
times 5 minute washes with PBS containing 0.1% Tween-zo, membranes
were incubated with either antl-rabblt Ig<3conjugated with horseradish
peroxidase (Jj :2000) or gamma chain specific anti-mouse IgG conjugated
with horseradish peroxidase (1:3000) (Zymed, S. San Franslco CA, USA))
for one hour at room temperature. Membranes were washed as stated
above, and lmmunoreacttve proteins were detected by enhanced
chemiluminescence (EeL; Arnersham, Arlington Heights, IL, USA).
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2.20 In vitro protein kinase assays
Immunopreclpttatlons were carried out as descrlbsd (see section 2,18).
Immune complexes were washed three times with NP-40 lysis buffer and
twice with !<lnase buffer (25mM Hepes, pH 7.5, 6.2SmM MgCI2 and 12.Smf\t1
MnCI2). Following the addition of 20~tC, ot ['Y.32P]ATP (60lJOCi/mmol; Dupont
NEN, Boston, MA, USA) in 1O~I of kinase buffer containing 100;.tM sodium
orthovanadate, samples were incubated at 37°C for 30 minutes. An equal
volume of 2X Laemmll sample buffer 'Was added and phosphorylated
protelne were analysed by 80S-PAGE.
2.21 Sucrose gradient sedimentation
Stable transfectants and SUP-M2 cells were lysed In either NP-40 lysis bufffJr
or CSK buffer (10mM Pipes, pH 7, 100mM KCI, 0.5% NP·40, 300mM suerose
and 3mM MgCI2). Lysates were layered over 4.5-ml gradients of 5 to ~W%
suorcce In either Np·40 lysis buffer or 20mM Trls-Hol, pH 7.5, 100tnM NaCI
and 0.1% Np·40. Gradients were centrifuged at 4°0 for 6 to 8 hours In ::t
Beckman SWSO.1 rotor at 45 OOorpm. Fractions of 250~1 were collected
from the top of the gradient, immunopreclpltated with either antiwALK #11
or antiMMET Ab143, and assayed ln vitro for kinase activity or subjected to
Western blotting following SDS~PAGE. Native molecular weight markers
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(horse apoferritin (443kD), ~..amylase (200kD), alcoriol dehydrogenase
(150kD), bovine serum albumin (66kD) and carbet de anhydrase (29kD)
(Sigma, St. Louis, MO, USA.» were analysed in parallel gradients. These
fra,';7tiGlnswere mixed with an equal volume of 2X Laemmli sample buffer,
resolved by SOS-PAGE, and detected by staining the gel with Coomassle
blue.
2.22 In vivo tumorigenicity assay
Clonal stably transfeoted Fr3T3 or parental oells (5X1DB) were washed with
PBS and resuspended in 200lli PBS. The cells were Injected subcutaneously
Into the back of NOD/LtSzdsoid mice (Jackson Laboratories, Bar Harbor,
ME, USA) (Shultz et at., 1995). Tumou torrnatlon was monitored for 10
weeks.
~ I
o3. RESULTS
3.1 Transient expression of NPM-AlK, TPR-MET and mutant
proteins In COS..7 cells
Following the cloning of the DNA constructs into the retrovtral vector
pSRaMSVtkneo (section 2.14), the constructs were tested for expression in
lmmunopreclpltatsd with the appropriate antibody, and expression was
COS~7 cells. Lysates from transfec=d COS~7cells (section 2.3) were
assessed by either in vitro kinase assay or by immunoblottlng (sections
2.18, 2.19 and 2.20). Consistent with the calculated molecular mass, each
irrmunoprecipltated protein migrated at the expected size: NPM-ALK,
75kDa; TPR-MET, 60-65kDa; TPR-Al.K, 78kDa; NPM..MET, 55kDa; M51719LNPM ..
ALK, 75kDa; !(210RNPM_ALK, 75kDa; L\MBNPM-Al.K, 74kDaj A64NPM-ALK, 6akDa;
reasons unknown, AMBNPM-ALK and A64NPM..ALK did not exhibit in vitro kinase
L\9S.103NPM_ALK, 711<Daand AC154NPM_ALI<, 5akDa (figure 3.1 A and 8). For
activity In transtected COS-7 cells, and thus the lmmunopreclpltates from in
i, j
)
I,,..
vitro transcribed and translated protein (section 2.17) were tested for In
vitro kinase activity. Both ,6.MBNPM..ALK and A04NPM-ALK expressed In this
way exhibited catalytic activity In vitro (figure 3.1 C).
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r:lgure ,'3.1. NPM-ALK, TPR-MET and enginel3red mutants are efficiently
expressed in COS-7 cells. (A), (8) COS-7 cells were transiently transtected
with the indicated DNA constructs in the retrovlral vector pSRaMSVtkneo,
and tested for expression. (A) Catalytic activity of NPM-ALK mutants was
tested by in vitro kinase assays, as described In section 2.20 of MaterialS
and Methods. Lysates from COS-7 transtected with empty vector (lane 1),
NPM ..ALK, TPR-ALK, M5f710LNPM_ALK,~65.103IVPM_ALK or ~C154NPM_ALK, and
from the SUP-M2 oell line were Immunoprecipitated using anti-ALK #11
(1 :1(0). Lysates from COS ..7 transfected with empty vector (lane 2), TPR-
MIET and NPM-MET were immunopreoipltated with anti-MET Ab143 (1:1000).
(8) Lysates from C08-7 transfected with the Indicated DNA constructs
were lrnmunopreolpltated with antl-ALK #11 and immunoblotted with ALK-1
(1 :500). (C) Because the in vitro autoklnase activity of the AMBNPM..ALK and
AS4NPM-ALK proteins expressed in COS-7 cells was difficult to demonstrate
for reasons unknown, in vitro transcribed and translated proteins were
Immunopreoipltated with anti-ALK #11 and tested for in vitro kinase
activity. All proteins were resolved by 7.5% SOS·PA(~E. Each protein Is
indicated by an arrowhead: NPM-ALK, 75kOa; TPR-MET, 60-65krJa; TPR-
ALK, 78kDa; NPM ..MET, 55kDa; MSnl9LNPM_ALK,75kDa; 1<210ANPM-ALK,75kOa;
AMBNPM-AU<, 74kDa; ~64NPM-AU<, 68kDa; A6S.f03NPMaALK,11kDa and
t.\C154NPM_ALI<, 58kDa. The high molecular mass bands seen In (A) lanes 3, 7,
and 9, and (8) lanes .2 and 5, probably represent oligomeric complexes of
the Indicated protein that are too large to be resolved In these gels.
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3.2 Transformation of FI'3T3 fibroblasts by NPMnALK
To test the onooqenlc potential of NPM-ALK, the entire coding sequence was
cloned into the rstrovlral vector pSROGMSVtkneo(section 2.14) (Muller et al.,
1991). Helper-free retroviral stock, prepared by transient hyperexpresslon
in 293T cells co-transfected with this NPM-ALK construct together with the
'V2 packaging construct, was used 'to infect low-passage-number Fr3T3
fibroblasts (sections 2.3, 2.4, ~1,5and 2.6) (Pear et aI., 1993). Fibroblasts
infected with retroviral stock prepared using "empty" pSRaMSVtkneo as a
control did not yield anchoraqe-lndependent clones in numbers greater than
observed as spontaneous background with the parental Fr3T3 cells (figure
3.2 A and B). By contrast, cells Infected with NPM~ALK rstrovlral stock
formed multiple anchorage-independent clones of densely packed cells which
were visible 5 to 14 days after plating In soft agar (figure 3.2 C). Fr3T3
cells infected with rstrovlral stock prepared using the TPR-MET construct
were used as a positive control (Flxrnan et al., 1995j Rodrigues and Park,
1993) (figure 3.2 D). Anchorage-Independent colonies were photographed
at a magnification of 10X to illustrate the morphology of the Individual
clones (figure 3.3 A-D).
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Figure 3.2. Anchorage-Independent growth of Fr3TS cells expressing the
indicated protein. Equivalent numbers of cells (5X103) were seeded In soft
agar 72 hours after infection. (A) Uninfected parental Fr3TS, (8) "empty"
pSRaMSVtkneo retroviral vector, (0) NPM-ALK, (0) TPR-MEi, (E) TPR-AU<,
(F) NPM-MET, (G) MSnl9LNPM_ALI<,(H) K210RNPM·ALI<,(I) LiMBNPM-ALK, (J)
,6.64NPM-AL.K, (K) LiElS'103NPM_ALK,(L) LiC154NPM-ALK.The soft agar plates
were photographed after two weeks In culture.
70
A B !~.~wr;'~
()
•'. i'~.'','~,..•....~,
~, !\: ' :. ;-
',"\1 :
0".4) E
(? • F •
G •
•
\
,
• •.tf-··--··--~~- I, ,
J' K . L
\._;
Figure 3.3. Anohoraqe-lndependsnt growth of Fr3TS cells expressing the
indicated protein (magnified), The soft agar cloning dishes in figure 3.2 were
photographed at I~10X magnification to show Individual clones. (A)
Uninfected parental Fr3T3, (8) "empty" pSRaMSVtkneo retrovlral vector,
(0) NPM ..ALK, (D) TPR·MET, (E) TPR·ALK, (F) NPM·MET, (G) M5f7/0lNPM_ALK,
(H) 1(210RNPM_ALK,(I) ~MBNPM·ALK, (J) il64NPM-ALK, (K) il65•103NPM-ALK, (L)
~C164NPM-ALK,
Further evidence of NPM-ALK-induced transformation was provided by focus
formation assays (section 2.7). Infected Fr3T3 cells were cultured in
100mm tissue culture dlshes for 10 to 14 days and then stained with
Giemsa. Fr3T3 cells Infected with NPM-ALK retrovlral stock formed
numerous fool (flgL,(e 3.4 C). Fibroblasts infected with viral stock prepared
using TPR-MET served as a positive control (figure 3.4 D). Fr3TS cells
infected with retrovirus using "empty" retroviral vector exhibited a low
background of focus formation which was comparable to that of parental
Fr3T3 cells (figure 3.4 A and B). F!broblasts infected with NPM-ALK viral
stock were densely packed, morphologically transformed cells that
coalesced upon further growth to form sheets of abnormal cells, whereas
parental cells and those expressing "empty" vector exhibited a normal
untransformed morphology (figure 3.5 A-D).
In vivo tumorigenicity of one Fr3T3 clone expressing high levels of NPM-AI.K
(designated NPMMALKclone #1) was assessed by subcutaneous injection of
5X106 cells into the back of each NOD/LtSz-scld mouse (section 2.22).
Tumours with an average diameter of approximately 20m formed In 6 to 14
days at the site of injection (figure 3.6 A and B). No tumours formed in the
mice Injected with either parental Fr3TS cells or Fr3T3 cells ~~xpressing
"empty" pSRaMSVtknec, even after 10 weeks,
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Figure 3.4. See figure h:gend on tile following page.
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Figura 3.4. Focus formation of NPM-ALK, TPR-lv1E'r and engineered mutant
proteins. Fr3TS fibroblasts were Infected with retrovlral stock prepared
using the Indicated construct, seeded into 100mm tissue culture dishes, then
stained with Giemsa after '10 to 14 days in culture. (A) Unlnfected parental
Fr3TS, (8) "empty" pSRcx.MSVtkneoretroviral vector, (0) NPM-ALK, (0) TPR-
MET, (E) TPRuALK, (F) NPM ..MET, (<3) M51719LNPM_ALK, (H) K210RNPM-ALK,(I)
tlMBNPM-ALK, (J) i\o<NPM-ALK, (K) A65•103NPM·ALK, (L) tlC154NPM-/\LK
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Figure 3.5. Morphology of Fr3T3 cells expressing NPMNALK, TPRMMET and
engineered proteins. (A) Unlnfected parental Fr3T3, (8) "empty"
p,.,R<xMSVtkneo retroviral vector, (C) NPMMALK, (0) TPR ..MET, (E) TPR ..ALK,
(F) NPM"MET, (G) MSf1I9LNPM·ALK,(H) K210RNPM..ALK, (I) aMBNPMMALK, (J)
L\G4NPM ..ALK, (K) L\G5.103NPM..AU<, (L) .1C154NPM.ALI<.
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Figure 3.6. In vivo tumorigenicity of NPM·AU<. f\JOD/LtSz-sold mioe were
subcutaneously injected with 5X106 clonally-derlved parental Fr3T3 cells or
clonal fibroblasts expressing either "empty" pSRaMSVtkneo or NPM-ALK.
Tumours with an average diameter of approximately 2cm formed In EIto 14
days at the site of injection in both the male and female mice. (A) Female
mice injected with either parental Fr3T3 cells or clonal Fr3TS cells expressing
NPM·ALK. (9) Male mice injected with clonal Fr3T3 cells expressing ellher
"empty" vector or NPM-ALK
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Figure 3.G. In vivo tumcrlaenlctty of NPMwALK. NOD/LtSz-scid mice were
subcutaneously Injected with 5X1 06 clonally-derlved parental Fr3T3 cells or
clonal fibroblasts expressing either "empty" pSRaMSVt'<I1Poor NPM4\U<.
Tumours with an average diameter of approximately acm formed In 5 to 14
day!:) at the site of Injection In both the male and female mice. (A) Female
mice Injected with either parental Fr3T3 cells or clonal Fr3T3 cells expressing
NPMwALK. (8) Male mice injected with clonal Fr3T3 cells expressing either
"empty" vector or NPM·ALK.
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3.3 Transformation of fibroblasts by NPM·ALK requires the
kinase activity of the truncated ALK protein
The characterisation of other truncated, fused receptor tyrosine kinases
such as TPM3-TRK and TPR-MET has indicated that their oncogenicity is
dependent upon the ability of the respective kinase to phosphorylate cellular
subsjrates, some of which relay mitogenic signals to the cell nucleus
(Rodrigues and Park, 1994). To confirm that the Intrinsic kinase activity 01
ALK is required for NPM-ALK..mediated transiormation, a kinase-defective
mutant, 1(210RNPM_ALK,was prepared In which the Invariant lysine residue In
the ATP-blndlng region at the catalytic domain of protein kinases was
changed to an arginine (section 2.14) (Hanks et al., 1~88). As expected,
th~ K21orlNPM..ALK mutant failed to transform fibroblasts (figures ~.2 H, 3.3
H, 3.4 Hand 3,5 H).
Another mutant, A0154NPM-ALK,was analysed In which the ALK portion 01
the chimaera was altered by deletion of the carboxy-terminal 154 amino
acids (section 2.14), This mutant was prepared to determine if these
carboxy ..termlnal residues, which include the potential SHe and IRS"i binding
site NPTy667,are required for tra.nsformatlon (van der Geer and Pawson,
1995). FraTS fibroblasts were infected with retrovlral stock prepared using
~01S4NPM"ALK., Daletlor, of this large portion of the carboxy ..terminal tail of
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ALK only slightly reduced the transforming activity as compared to wild-
type NPM-ALK (figures 3.2 L, 3.3 L, 3.4 L, 3,5 Land 3.7). Lysates from SUP~
M2 cells or from 293T cells transtscted with L\C164NPM-ALK were
irnmunopreclpitated using either anti-SHe or antl-Al.K antibodies (section 2.3
and 2.18). These results revealed that wild-type NPM-ALK associated
physically with SHC, whereas L\C154NPM-ALK failed to do so (figure 3.8),
Indicating that NPTyStl7 Is a SHe binding site.
3.4 An intact NPM segment is required for tranetormatlcn by
NPM-ALK
The absence of any sequence differences between the portion of ALK
present In NPM·ALK and the corresponding re~Jion of the full-length normal
receptor suggested that the NPM residues of the chimaera function to
activate its transforming ability (Morris at al., 1994; Morris at al., 1996). To
examine this possibility, three deletion mutants of NPM-ALI< were prepared
in w.uoh non-overlapping portions of the 118 amino acid NPM were removed:
L\G4NPM.ALK, in which the amino-terminal 64 residues are deleted; L\65'103NPM_
ALK, in which amino acids 65 to 103 are absent; and L\MBNPM-ALK, in which
residues 104 to 115 that comprise a C..Xs"H ..X4"H motif of unknown function
and referred to as a putative metal-binding domain are removed (section
2.14) (Chan et al., 1989) (figure S.7). Each of these NPM deletion mutants
18
."
CE
C
"'It
(tl
(;.)
~
sr
(t
ct
~.
cOc:
"'""m
(J)
co
(i)
:::I
0.
0
:::l
---:::::r
---s (J)
CO 0'
0
:iE
:::l
CO
"0
Sll
CO
(])
11BaaNFM 562 aa AlK
No. foci Subcellular Localisation
Cytoplasmic Nuclear
OUgomerisation
COOH 1310
NFM-AlK ~~~
Me I(inaooDomain
142aa TPR 381aaMETI -----,--~~~--
NiI2
TPR-MET t,~,~1§3$SSS$illllmllllllllllllllllll~%~H
LZI.Z Kinase Domain
N"rl2 COOH
TPR-ALK rggmi§~~-- - ~ .r: -_--~ '"
NH2
N~ETB ~··:'=:.·:·:::::·:::l·:i~~~%R~~~~mllllmllimllrnm""mTT1I11-rnIlI-IlI....!:~r~R3H
NH2 COOH~~." ~--: ..-- ~~USl:J..NFM-ALK _
ttt
rom COOH
l<2!CrlNI'M-AU< ~-:::.-<~-.~~~~..
NH2 coon
_6.'ABNFM-AlK I-:·:-:-:·:l ~-o • ~ - - . - ~~
NH2 COOH
AC4NFM-AlK t::::~ ~'&.~~VATG
NH2 COOH
A55-1C3l1iP,....AlKI:·:.:l :~- ~ __ ;.. • o<~~
NH2
AC'S<NPM-AlK f:·:·:·:·:·I\..~-:' .-'< _ -. ,.~
_- __ -_ - _ .. _-~
COOH
y y y
2560 I Y Y N
I950 Y y N
480 Y y y
1280 Y Y Y
0 ND Y y
0 N y N
0 N y N
0 N Y N
970 I ND y Y
---C_=-==~~=.=3?
Figure 3.7. Schematic of NPM-ALK mutants. Diagrammatic representation
of wlld-type NPM-ALK, the NPM-ALK mutant proteins analysed In this study,
and the wild-type TPR-MET protein are i1lu~tratEld(Rodrigues and Park,
1993). Indicated moth,~include the putative metal-binding (MB) domain on
NPM·Al.K and the leucine zipper (LZ) regions of TPR-MET. The transforming
capability (as Indicated by the average number of foci per 100mm dish),
ability to oli~lomerise, and subcellular location of each protein are indicated
to the right.
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Figure 3.8. Association of NPM-ALK and :C154NPM_ALK with SHe. Lysates
from 293T cells transfected with L\c154NPM-ALK, or from SUP-M2 cells, which
express wild-type NPM-ALI<, were Immunoprecipltated with either antl-Al.K
#11 (1:100) or polyclonal anti-SHe (1:80). To examine co-
immunoprecipltation of SHe with either NPM·ALK and/or L\C154NPM-ALK,
PVDF membranes were immunoblotted, as indicated, with either ALK·1
(1:50) or monoclonal anti-SHe (,I:260). IP: immunopreclpltatlon: PI: pre..
immune.
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failed to transform Fr3T3 fibroblasts as judged by either soft agar colony
formation (figures 3.2 I..K and 3.3 t·K) or focus formation (figures 3.4 I-K
and 3.5 I..K). Importantly, although all of the three mutants could be
demonstrated to possess autokinase activity In vitro (figure 3.1 A and C),
none exhibited kinase activity in vivo {figure 3.9}.
3.5 Stable expression of NPMuALK, TPR-MET and engineered
mutants In Fr3T3 cells
A number of clonal cell lines were derived from each of the infected Fr3T3
fibroblast lines (section 2.7). Infected Fr3TS were either selected in G418-
containing growth medium and individual clones were isolated Utilising cloning
rings, or anchorage..lndependent clones were picked from soft agar. These
cell lines were tested for expression by either in vitro kinase assay or by
Immunoblotting (section 2.19 and 2.20). Each protein was efficiently
expressed in the Fr3T3 cells (figure 3.10 A and B).
3.6 NPM-ALK exlsts In vivo as an oligomeric complex
Llgand ..mediated activation of the catalytic function of receptor tyrosine
klnases is thought to be generated by receptor dimerisatlon, resulting In
Intermolecular crose-phosphorylatlort and the ability to phosphorylate
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Figure 3.9. In vivo 'tyrosine phosphorylation of NPM..ALK and selected NPM-
ALK mutants. Lysates from clonal Fr3TS cells expressing the indicated
proteins, and from SUP ..M2 cells were Immunoprecipltated using either anti ..
AU( #11 (1:100) or antl-phosphotyroslne (antl-P» Tyr) (1 :250). After
transfer to PVDF membranes, proteins were lmmunoblotted with anti-ALK
#11 (1:500).
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Figure 3.10. See figure legend on the following page.
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Flgu:,~3.10.Representative clonal Fr3T3 cell lines showing the expression
of NPM-ALK, 'TPR~METand mutants. (A) The catalytic activity of NPM-ALK
mutants was tested by in vitro kinase ascays. Lysates from parental Fr3T3
cells (lane 1) and from those cells expressing empty vector (lane 2), NPM-
ALK, TPR-Al. K, M5I7/9LNPM~ALK,and L\C154NPM-ALK were Immunopreclpitated
using anti, 'LK #11 (1:100). Lysates from parental Pr3T3 (lane 3) and
those e'."pl\i)ssingempty vector (lane 4), TPR-MET and NPM-MET were
immunopteclpltated with anti-MET Ab143 (1:1000). (8) I..ysates from Fr3T3
cells uxpresslng J1e Indicated protein were sequentially tmmunopreolpltated
and immunoblotted with antl-Al.K #'11 (1:500).
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cellular substrates (Ullrich and schlecslnqer, 1990). The fact that the NPM-
ALK oncogene product has constitutive kinase activity in vivo (figure 3.9)
su~gests that the chimaera has the ability to form dlmers Of higher-order
ollgomers independent of ligand stimulation.
To determine if ligand-Inde~endant dimerisatlon of NPM-AU< occurs, the
tormauon of NPM·ALK complexes In vivo was examined. SUP-Iv12 cell lysates
were layered on 5 to 20% sucrose gradients, and the sedimentation profile
NPM-ALK was determined after centrifugation. Fractions collected from
the gradients were assayed for the presence of NPM-ALK proteins by in
vitro kinase assay (!,~ectlons 2.20 and 2.21). NPM-ALK-assoclated kinase
activity was found distributed over several gradient fractions, with a peak
s.lightly gll'eater than 200kDa (figure 3.1'1 A) .. larger than the approximately
150kDa s'ze predloted for NPM..ALK homodtmers, In addition to forming
horno-ollqomers In vitro (figure 3.11 C} and In vivo (figure 3.11 A), NPM-ALK
was found to form hstero-ollgomers with normal NPM in vivo (figure 3.11
D).
1'0 determine if the loss of transforming ability and In vivo klnase activity clf
the NPM deletion mutants tlS4NPM~ALI<. tlG5.103NPM~ALK,and ilMBNPM ..ALK
correlated with the Inability of these proteins to ollqomerlse, similar sucrose
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Figure 3.11. See figure legend on page 89.
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Figure 3.H. See figure legend on the following page.
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FigW'e 3.11. Ollqomerlzatlon of NPM·ALK and selected NPMwALK mutants.
(A), (B) Cells from the t(2;5)-positlve lymphoma cell line SUP-M2 (for NPM~
ALK) or clonal FraTS cells expressing either A65.103NPM_ALK,NPM-MET,
AMBNF)M'ALK or L\G4NPM-ALK were lysed in NP-40 lysis buffer, while Fr3T3 cells
expressing TPRwALK were lysed in CSK buffer. Lysatas from SUp..M2 cells and
from l:::r3T3 cells expressing either L\GS.l03NPM..ALK, NPM-MET, AMBNPMuAL.Kor
L\64NPM-AlK were layered over 5 to 20% sucrose gradients oontalnlnq Np·
40 lysis buffer, whereas Iysates from Fr3T3 cells expn::1'$sing TPR ..ALK ware
layered over a 5 to 20% gradient containing 20mM Trts, pH 7.5, 100mM
Nael SInd 0.1% NP-40. The number above each lane corresponds to the
fraction number from U'6 IIghte$it fraction to the heaviest. PrO~ehlJ were
separated bV SDS ..PAGE under reducing conditions. Fractions were
immunopreolpitated using either anil-ALK #11 (1:100) (for NPM-ALK, .166•
103NPMwALK,TPR-ALK, ~.MsNPM-AL.K and /l64NPM-ALK) or antl~MET Ab143
(1:1000) (for NPM ..MET) and then assayed for activity by in vitro kinase
assay (A) or by Western blotting (B). The monomeric forms of NPM~ALK
(7SkDa), Ji65.103,IJPM-ALK(71 kDa), TPR-ALK (78kDa), NPM-MET (55kDa),
L\MBNPM-ALK (74kOa) and A04NPM-ALK (68kDa) are shown. (C) NPM~ALK, the
indicated mutants of NPM-ALK and NPM were transcribed and translated in
vitro. Unbolted samples were resolved by 6% 80S-PAGE under reducing
conditions, as previously described (ULI and Chan, 1991). The monomeric
term of each protein Is shown by an arrowhead: NPM-ALK, 75kDa;
M51710LNPM_ALI<,75kDa; i\MBNPM-ALK, 74kDa; L\64NPM-ALK, 68kOa; A6~.103NPM~
ALK, 71 kOa; NPM-MET, tiSld)a; and NPM, 381<0a. (D) NPM-ALK Is physically
assoclated with normal NPM In t(2;5)-posltive lymphoma cells. Gradient
fractIons ,of SUP-M2 lysates were lmmunopreolpltated with antiNALK #11
and lmmunoblotted with either anti-AU, #11 or antl-823.
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gradient fractionations using Iysates from Fr:.iT3 cells stably expressing
each mutant were performed, Although each of ths J proteins distributed
within the gradients at somewhat different relative molecular masses, all
three sedlmented with a peak significantly smaller than that of t'1e wild-type
chlmaeric protein (figure 3.111 A and B). The results obtained from the
sucrose gradient fractionations for AMBNPM-ALK and A~4NPM-ALK were
lnconcluslvs, and as such further experiments were performed. To determine
whether or not the NPM delatlon mutants could homo-ollqomerlse, in vitro
transcribed and translated proteins that had not been balled were resolved
by SDS~PAGE(figure 3.11 C). Whereas NPM-ALK was able to homo-
oligomerise In vitro, none of the NPM deletion mutants were able to do so,
Indicating that complex torrnatlon was Indeed Inhibited by these alterations
of the NPM moiety. Furthermore, AMSNPM-ALK was unable to associate with
normal NPM (data not shown). That complex formation Is mediated by the
NPM portion of the 'fusion Is consistent with data Indicating that normal NPM
exists in vivo as a homo-oligomer (Llu and Chan, 1991; Yung and Chan.
1987).
structure-tuncncn study of normal NPM has suggested that, within the
arnlno-termlnal region that mediates hcmo-ollqomerlsatlon, rnethlonlne
residues at positions 5. 7 and 9 are essential for oligomer formation {Llu
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and Chan, 1991}. Therefore an engineered NPM-ALK mutant prot-in,
M51710LNPMuALK,in which these residues were changed to leucines,
recapitulating mutations reported to Inhibilt normal NPM hexamer 'formation.
Interestingly, M51719LNPM_ALKsedlmented In sucrose gradients as a complex
identical in mass to the Wild-type NPM·ALI< (data not shown), and was able
to homo-ollqomerlse in vitro in a similar fashion to NPM..ALK (figure 3.11 C).
This mutant protein was efficiently phosphorylated in vivo (data not shown),
and transformed Fr3T3 with the same potency as the wild-type ohlrna=ra
(1lgw'es 3.2 G, 3.3 G, 3.4 G, 3.5 G and 3.7). These results suggest that the
exact residl es required for NPM homo-ollqomerlsatlon versus NPM and r~PM-
ALK heterodlmerlaetlon may differ somewhat.
Although providing evidence that the NPM portion of NPM-ALK serves as an
oligomerlsation motif, the above experiments do not rule out the possibility
~!'Qx this segment could perform other functions critical ror transformation.
To better address this issue an ALK mutant protein , TPR-ALK, was
prepared, In which NPM was replaced with the residues of the '"PR proteln
that are present in the TPR..MET oncogene (section 2.14) (Park at al.,
1986). This portion of TPR, a nuclear pore protein, contains two leucine
zipper motifs that have been shown to mediate dlmerlsatlon of TPF{wMET
and prodluce Its constitutive kinase activation (Byrd at al., 1994). No other
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functions in TPR ..MET have been demonstrated for these TPR activating
sequences. The activation of ALK transforming activity by a fusion partner
with no homolcgy to NPM, such as TPR, would support a singular function
for NPM in NPM ..ALK oligomerlsatlon. Determination of the oligomerisation
state of TPR ..ALK isolated from stably-expressing Fr3T3 using sucrose
gradients showed the protein to exist in vivo as a multimeric complex
greater than 200kDa (figure 3.11 A). Transformation of Fr3T3 fibroblasts
by TPR·ALK was efficient, being only slightly less potent than NPM-ALK itself
(figures 3.2 E, 3.3 E. a.4 E, 3.5 E and 3.7). The reciprocal mutant, NPM-MET,
was generated t'" ascertain whether NPM sequences could activate a
heterologous truncated receptor tyrosine kinase (section 2.14). In addition
to being autophosphorylated in vivo (data not shown) and sedimentlng in
sucrose gradients as a complex of roughly 100-200kDa (figure 3.11 A),
NPM-MET was shown to homo-ollqomerlse in vitro (figure 3.11 C).
Fur,\hermore, this NPM-MET mutant protein transformed Fr3T3, although
with only approximately one-fifth the efficiency ('if TPR ..MET (figures 3.2 F,
3.3 PI 3.4 F and 3.5 F and 3.7). The reasonts) fOr the low transforming
ability of NPM-MET in comparison with either NloM-ALK or TPR-MET are
unclear. TPR-MET is localised to the cytoplasm, whereas NPM-MET Is found In
the nucleus (figure 3.12 E and 3.12 G), The unusuai location of this MET
fusion protein may alter its ability to transtrorn fibroblasts in that the levels
of NPM~Mr:T found in the cytoplasm may be Just below that required for
transformation. An alternate explanation would be that NPM-MET is
expressed at lower levels than TPR~MET and NPM~ALK. however, this Is
Improbable (see fit~urf:J3.10 A).
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3.7 Transformation by NPM·ALKdoes not require localisation
to the nuclear compartment
Cell fractionation (performed by S.W. Morris) and immunofluorescent
staining (section 2.16) demonstrated that the NPM-ALK In the t(2;5)-
positive cell line SUP-M2, was found in both the cytoplasm and the nucleus
(figure 3.12 A). K562, a t{2i5)-negative cell line, was used as a negative
control (figurs 3.12 B). The normal shuttling function of NPM together with
the observation that NPM and NPM-ALK heterodimerise, suggests that the
nuclear location of the chimaera results from NPM-medlated protein
translocation since the nuclear localisation signals of NPM are not present In
NPM-ALK (Borer et al., 1989; Chan et al., 1989; Dumbar et al., 1989;
achrnldt-zaohmann end Franke, 1988; Schmldt-Zachmann et al., 1987).
Therefore, if this hypothesis Is correct, the mutant proteins L\o4NPM..ALK, L\os.
103NPM-ALK, and L\MsNPM..ALK that fail to heterodlrnerlse with NPM would be
predicted to be completely cytoplasmic. To determine the subcellular
location of these proteins lmmunostalnlng experiments were performed with
the monoclonal anti·ALK-1 antlbor'v USing 00S- 7 cells transiently transfected
with each mutant construct (Pulford et al., 1996). Simultaneous OAF'I
staining was performed to clearly Identify cell nuclei. None of these three
mutant NPM·ALK proteins were present within the cell nucleus (figure 3.12 G..
I). To provide additional evidence that shuttling by NPM can produce nuclear
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Figure 3.12. See figure legend on the following page.
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Figure 3.12. Subcellular localisation of NPM-ALl<, TPR-MET, and engineered
mutant proteins. Cells were Immunostained using either the ALK-speclfic
monoclonal antibody AU(-1 (neat) (all panels except D, D', F and F') or the
h-ME"r (028) antibody (1 :500). Simultaneous staining with DAPI was
performed to visualize the nuclei of the cells (panels A'to J'). (A, A') t(2;5)-
positive lymphoma cell line SUP-M2, (8, B') t(2;5)-negative chronic
myelogenous leukemia cell line K5t32,(C, C') NPM-ALK, (D, 0') jPR-MET, (E,
E') TPR-ALK, (F, F') NPM-MEi, (G, G') ilMBNPM-ALK,(H, H') A64NPM-ALK, (I, 1')
A$'5·103NPM-ALK,(J, J') MS/1/Ui NPM~ALK. All cDNA constructs were expressed in
C08 ..7 cells (panels C, C' to J, J').
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localisation, t:,e subcellular location of the NPM~METprotein was determined.
Because TPR~MET is completely cytoplasmic (figure 3.12 D), localisation of
NPM~METto the nucleus would have to be dependent upon the NPM portion
of this fuslofl. Immunofluorescent staining of C08 ..7 cells expressing NPM..
MET revealed a pattern of both cytoplasmic and nuclear stalnlnq (figure
3.12 F) qualltatlvely Identical to that observed with Wild-type NPM-ALK
(figure 3.12 C). Lastly, despite Its ability to transform fibroblasts as
efficiently as NPM..ALK, the TPr. ·At_;{mutant protein was localised within the
cytoplasm (figure 3.12 E).
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4. C:SCUSSION
The fusion of a nucleolar protein, NPM, to a tyrosine kinase, ALK, raises
novel questions about how such a chlmaeric protein might function
(Sawyers and Denny, 1994). Because the normal ALK receptor Is 'expressed
only In neural tissues, clearly one resutt of this gene fusion is the ectopic
expression of ALK in lymphoid cells, driven by the strong NPM promotor
(Morrls at al., 1996). It was demonstrated that the NPM"ALK protein
possesses constitutive phosphotransferase activity In the absence of any
mutations within the ALK segment and this ImHcates that the NPM moiety
serves as an activating sequence. Lastly, although the nuclear localisation
signals of NPM are not incorporated into the chimaera, the prior
demonstration that the normal NPM protein exists as a horno-ollqomer
shuttling proteins between the nucleus and the cytoplasm suggests that
NPM~tTledlat\.r:Inuclear localisation of NPM"ALK could expose the fusion
protein to a new range of kinase substrates required for cellular
transformation (Adachi et al, 1993; Borer et al., 1989; Chan at al., 1989;
Durnbar at al, 1989; Fankhauser el(al., 1991; Schmidt-Zachmann and
Franke, 1988; Schmldt-Zachmann et al., 1987). The presence of NPM-ALK
within the nucleus could potentially also alter normal cell growth by
interfering with other functions of ii, "mal NPM, which are reported to include
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roles In the enhancement of chain elongation during DNA repllcation,
ribonuclease activity, and regulation of the acti\,ity of certain transcription
factors such as the YY1 protein and an Incompletely characterised factor
that controls the expression of the p120 prouteratlon-assoclated nucleolar
protein (Chatterjee et aI., '1991; Feuerstein et al., 1990; Herrera et al.,
1995; Inouye and Seto, '19&4; Pc.er et al., 1990). These potential functions
tor the NPM portion of NPM-ALK have been addressed in this thesis by
assessing the effect on the transformation potential of the chimaera of
vartous NPM deletions or substitutions.
Previous analyses of truncated oncogenic protein tyrosine kinases have
Identified two apparent types of fusion partners. Fusion partners 1I1<'ilthe
non-muscle tropomyosin (TPM3) or translocated promotor region ('rl:1R)
genes round Initially In the TPM3- TRK and TPR-MET oncogenes, respectively,
appear to mediate dlmerlsatlon of the fusion proteins, resulting in
constitutive tyrosine kinase activity of their protein tyrosine xlnase moieties
(Martin-Zanca et al., 1986; Park et al., 1t~86;Ullrich and SchlFJsslnger, 1990).
Although essential for transforrrcr 9 activity, these segments can be
Interchanged with other m~ltir:3 that result In proteln-proteln lnteraotlon
without loss of transforming activity of the resulting chimaeras. For
example, recombination of TRK kinase domain sequences during NIHSl'S
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transfectlon experiments with at least 14 different unrelated 5' end DNA
sequences produces transforming chimaeras (Kozma et al., 1988; Oskam
at al., 1988). Oncogenic fusion protein tyrosine klnases In naturally occurring
human tumours can likewise be comprised of unrelated arnlno-terrnlnal
residues fused to a common kinase partner, an example being the RET
papillary thyroid carcinoma oncogenes that can be formed by fusion with
dimerisatlon motifs encoded by either tha D10.'3170 or Ala genes
(Bongarzone at al., 1993; Grieco at al., 1994; Mlnoletti at af., 1994).
Furthermore, these various activating sequences are not necessarily specific
to a particular kinase partner but may qenerate the biologic function of
multiple e'ffector genes. For example, in addition to TPR-MET, TPR sequences
are fused to the TRK kinase domain In human papillary thyroid tumours and
form the amino terminus of an oncogenic RAF serine/threonine kinase In
experimentally ..induced rat tumours (Greco et al., 1992; King et al., 1988).
AE.~jefrom dlmsrlsatlon, tht:::o'9Is no evldsnce that these sequences serve
addlt!omll functions Important for oncage'lssla. The amlno-termlnal fusion of
SeR residues to the truncated ABL protein tyrosine kinase stands In
contrast to the tuslons that occur with partners like TPM3 or TPA. In
addition to mediating homo-ollqornerlsatlon of 13CR..ABL and hetero-
ollqomerlsatlon with normal BOR, the BCR residues In these chimaeras
perform multiple funotlons required tor BCR-ABL biologic activity, including
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transteotlon experiments with at least 14 c!H:erent unrelated 5' end DNA
seque- iss produces transforming chimaeras (Kozma at al., 1988; Oskam
et al., i9Ba}. Oncogenic fusion protein tyrosine klnases In naturally occurring
human tumours can likewise be comprised of unrelated amino-terminal
residues fUS~1dto a common kinase partner, an example being the RET
papillary thyroid carcinoma oncogenes that can be formed by fusion with
dlrnerlsatlon motifs encoded hy either \he D105170 or Ria genes
(80ngarlone et al., 1993; Grieco €It al., 1994; Minoletti at al., 1994).
Furthermore, these vatlous activating sequences are not necessarily specifio
to a particular kinase partner but may generate the biologic function of
multiple effector genes. F,,)r example, in addition to TPRoMET, TPR sequent...,Js
are fused to the TRK klnase domain In human papillary thyroid tumours and
form the amino terminus of an oncogenic RAF serine/threonine kinase in
experimentally-induced rat tumours (Greco et al., 1992; King et al., i988).
Aside from dlmerlsatlon, there is no evidence that these sequences serve
additional functions important for oncogenesis. The amlno-terrnlnal fusion of
eGR resldues to the truncated ABL protein tyrosine kinase stands in
contrast to the fusions that occur with partners like TPMS or TPR. In
addition to mediating homo-ollqomerlsatlon of 8CR-AS!" and hetero-
ollgomerlsatlon with normal eOR, the SCH residues In thbss chimaeras
perform multiple functions required for BCn·ABL biologic activity, Including
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(a) interaction with the SH2 domain of the substrate GR8-2 to activate the
RAS pathway, (b) Intrinsic serine/threonine kinase activity, (0) binding to the
ABL SH2 domain In a phosphoserine/phosphothreonine~dependent manner,
and (d) relocallsatlon of ABL from Its normal predominantly nuclear location
to the cytoplasm (Campbell at al., 1990; Maru and Witte, 1991; McWhirter
et al., 1993; Pendergast et aI., 1989j Pendergast et al., 1991; Pendergast et
al., 1993). In addition, differing portions of BOR present In p18SBCR.ABl.In
acute lymphoid leukaemia as compared to p210BCFloABLin chronic
myelogonous leukaemia result in five-fold higher kinase activity and greater
transforming ability of the p18S variant (Lugo et al., 1990). Substitution of
seR with unrelated sequences of comparable length renders the resulting
fusion ncn-tranetormtnq, as does mutation of the sequences known to
mediate the above-mentioned functions of BeR (Muller et aI., 1991).
The structure-function studies that are detalle..d here lndlcate that NPM
sequences of NPMGALK contain an oligomerisation domain, thn function of
which is .iosotutely required for the in vivo kinase activity of the chimaera.
The nature of the NPM oligomerlsatlon motif rernalns to be determined; for
example, computsr-asslsted analysis (COILS 2.0 (Lupus et al., 1991)) of the
NPM amino acid sequence fa!led to identify sequence similarity to other
oncogenic fusion partner prate-ins such as TPR, TPM3, SeR or TFG that
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contain coiled-coli domains that mediate oligomerlsatlon (Greco et at, 1995;
McWhirter at al., 1993; Rodrigues and Park, 1993). The demonstration that
any of three ncn-overlapplnq deletions that together encompass the NPM
portion of the chimaera inhibit complex formation Indicates that this entire
segment is necessary for cllqomorlsatlon to occur. The portion of NPM
present in NPM·ALK shares 47% amino acid Identity with the amino..terrt-lnus
of nucleoplesrnln, a pentameric protein that binds hlstones and transfers
them to DNA during nucleosome assembly (Dingwall et al., 1987; Dingwall et
al., 1982). This segment of nucleoplasmin is contained within an amino..
terminal core peptide released after proteolytic digestion that retains its
ability to form pentamers (Dingwall and Laskey, 1990). These structure-
function studles suggest that the 118 amino acid segment of NPM, and the
corresponding segment of nucleoplasmIn, represent the minimal motif
required for the horno-ollqomerleatlon of these proteins. Thus, like other
kinase fusion partners that have been characterised previously, NPM is
ubiquitously expressed and contains an ollgomerisatlon domain (Rodrigues
and Park, 1994). Although It was not unequivocally excluded that other
potential functions of the NPM segment of NPM~ALKcould be important for
transformation, the fact that a completely unrelated segment from the TPR
protein that Is known to promote ollpomerlsatlon can efficiently activate the
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transforming ability I)f the truncated ALK protein argues that other NPM
functions are unlikely.
The subcellular localisation of NPM-ALK suggests that the protein might
generate growth regulatory signals not only in the cytoplasm but also within
the nuclear/nucleolar compartment. Recent experlmental data support a
role for nuclear protein tyrosine kinases and their substrates in RNA
processing and trafficl{lng, transcriptional control of gene expression and
possibly other nuclear processes (Baskaran at al., 1993; Fumagalll et al.,
1994; Klpreos and Wang, 1992; Taylor and Shalloway, 1994). In addition,
several "cytoplasmic" protein tyrosine klnases including SRC, FER, and FGR
are now known to localise in part to the nucleus In some cells or under
certain conditions (Wang, 1994). The subcellular location of the engineered
NPMmMETprotein to the nuclear compartment Indicates that the NPM
moiety of NPM·ALK can mediate nuclear/nucleolar traffickln9 (most
probably by allowing hetero-cllqomerlsatlon with normal NPM), an
observation corroborated by the presence wlthln the cytoplasm only of the
three NPM deletion mutants LiG4NPM-AU<, tl6S-103NPM_ALKand _tlMBNPM-ALK.
Whether the lack of nuclear localisation, Independent of their failure to
horno-ollqomerlse and acquire constitutive kinase activity, Is responsible in
part for the Inability of these three mutants to transform cells cannot be
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determined. However, the efficient transformation of Fr3TS fibroblasts by
the cytoplasmic TPRwALK protein Indicates that nuclear localisation of an
activated ALK protein is not necessary for the rnallqnant conversion of
fibroblasts. Furthermore, the recent identification in anaplastic large cell
lymphoma of a rare variant t(1 ;2)(q25;p23) translocation that joins
activating sequences other than NPM to the ALK protein, producing a fusion
kinase restricted to the cytoplasm, Indicates that nuclear localisation is also
not required for lymphoid cell transformation (Pulford et al., 1996).
The signalling substrates utilised by NPMwALK in transformation are not yet
known. The presence in the chimaeric protein of a potential
phosphotyrostne ..blnding (PTB) motif (NPTyS67) prompted the examination of
the Interaction of the SHe protein tyrosine kinase su bstrate with wlld-type
NPM..ALK and with an engineered mutant, AC154NPM-ALK, lacking Its carboxy-
terminal "154 residues (including the NPTY motif) (Pelliel et al .. 1992; Sun at
al., 1991; van der Geer and Pawson, 19S)5). Whereas wild-type NPMaALK
physically associated with and phosphorylated SHC, 6,C154NPM-ALK was
unable to do so, suggesting that SHe binds the NPTy5G7motif 01 the
chimaera. Despite its inability to Interact with SHe, the AC154NPM ..ALK protein
efficiently transformed fib rub lasts, Indioatlng that SHe is not an essential
substrate for transformation and suggesting that another substrate with
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overlapping function such as GRB·2 may substitute for SHe activity
(t.owensteln et al., 1992). In a report published during the prep=ratlon of
this thesis, Fujimoto and co-workers Independently described the cloning of
the NPM·ALK cDNA and addressed the role of SHe and IRS..i "r' NPM·ALK·
mediated transformation using mutant constructs In which either or both
tyrosine residues 156 and 567 were changed to phenylalanine (Fujimoto et
al., 1996). In agreement with our data, SHe was found to bind to the
NPTy5G7 motif. Interestingly, both of the single point mutatlo- .naeras, as
well as the double mutant, transformed cells enlctently, irdicatlng that
neither IRS-1 nor SHe are essentlal for NPM..ALK·induced transformation, In
addition, wild-type NPM-ALK and all three point mutant chimaeras were
shown to efficiently associate with GR3..2.
Recent studies indicate that the role of NPM in malignancy is not restricted
to its involvement in the t(2;5), Analysis of the rare t(5;17) found in acute
promyelocytlc leukaemia has recently shown that this rearrangement results
In the fusion of the 5' end of NPM to the retlnolc acid receptor alpha (AARa)
gene to produce a ohlmaertc gene (Redner €~ :,..1 , .~~rJ.;). 'f'il~\ t(5;17)
generates two chimaerlc NPM-RARa proteins ..NPMn·RARa.which contains
the same NPM residues that are present in NPM-AU<. and NPML-RARa, which
possesses an additional 50bp from the NPM coding sequence plus 79bp of
104
coding sequence of unknown derivation. Both of these fusions contain the
same portion of RARa that is present in the more common promyelooytlc
leukaemia (PML)"RARa alla promyelocytic lsukaernla zinc finger (PLZF)-RARa
chimaerlc proteins (Zetent, 1994). The functions of NPM in NPM"RARa remain
to be determined, but it Is possible that the motif mediates homo-
dimerisation (as doer the PML segment of PML-RARa) resulting In altered
transcriptional properties of RARa (Doucas at aI., 1993; Kastner et al.,
1992; Pandolfi et al., 1991; Zelent, 1994). An alternative, but not mutually
exclusive, possibility is that NPM and NPM-RAHa hsterodlmers could localise
to speoflo regions within the nucleus, altering the subcellular location of
RARa binding partnsrs and thus Indirectly affec!lng normal RARa function
(Weis et al., 1994). It was determined that the t(3;5)(q25.1 ;q34j
rearrangement that is found in approxlrnately O.5~1% of all myelodysplastlc
syndromes and acute myaloid leukaernlas also involves NPM, prodUcing an
in-frame 'fusion of 5' end NPM sequences to those of a novel gene, that was
named myelodysplasla/myetclc lsukaemla factor (MLF1), whose deduced
amino acid sequence contains no regions oj homology with prevlously
characterised proteins (Yoneda-Kato et al., 1903). NPM..MLF1 contains 58
more NPM amino acids than do NPM..AU( and NPMs..RARa ruslon proteins,
Inc!udlng one of the two NPM nuclear localisation signals and most of the
glutamic and aspartic acid residues present in the two acid amino acid
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clusters of NPM. Immunostalnlng experiments indicate that MLF1 is normally
located In the cytoplasm, whereas NPM..MLt=1 is targeter.! to the nucleus,
with highest expression In the nucleoli. Like NPM-ALK, NPM-MLF1 can
heterodimerlse with NPM (S.W. Morris unpublished), probably contributing to
this relooaltsatton of the MLF1 protein. Structure·function analysis of NPM·
RARa and NPM·MLF1 similar to those performed here for NPM-ALK should
be of significant interest; In light of the fusion of NPM to three functionally
diverse proteins, It is liI<elythat the junctions of the NPM segment in each of
these three chimaeras will be found to be partially overlapping.
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5. CONCLUSIONS
Experiments were designed to investigate the transforming ability of NPM~
ALK, and the role of NPM fusion sequences in the oncogenic activation of
NPMNALK.
The oncogenic potential of NPM~ALKwas demonstrated in several ways.
Rodent fibroblasts stably expressing the chimaeric protein were able to
form anohorape-lndependent colonies in soft agar. In addition, 'fibroblasts
infected with retrovirus prepared utilising the NPM .. "'d_K retroviral construct
were able to form densely packed, morphologically transformed cells that
coalesced upon further growth to form sheets of abnormal cells.
Furthermore, mice Injected with clonal rodent fibroblasts stably expresslru,
NPM"ALK developed tumours at the site of injection as soon as five days
post..lnlectlon, Future studies could perhaps Investigate the oncogenic
potential of this fusion protein in haematopoietlc cells. The availability of
murine hasrnatopoletlc cell lines that grow only in the presence of lnterleukln-
3 makes this possible. The cells expressing NPM..ALK would be rendered
lnterleukln-s ..lndependent in the case of transformation due to the chimaera.
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It was demonstrated that the Intrinsic kinase activity of ALK Is required for
NPM-ALK'medlated transformation by the construction of a kinase-defective
mutant in which the Invariant lysine residue In the ATP-binding region of the
catalytic domain of protein klnases was changed to an arginine. As
expected, this mutant failed to transform fibroblasts. In addition, It was
shown that transformation by NPMuALKdoes not require the SHe binding
site located In the carboxy terminus of the ALI< portion in NPM~ALK. Further
Investigation is required to determine which substrates may be required for
the transformation by NPM-ALK. This could be achieved ty mutating
potential "substrate" sites and subsequently testing the transforming ability
of these mutant constructs.
An Intact NPM segment Is absolutely required for NPM-ALK-mediated
oncogenesis, as indicated by the observation that three different NPM-ALK
mutant proteins lacking non-overlapping portions of the NPM segment each
failed to form Oligomeric complexes, lacked klnaae activity In vivo, and failed
to transform cells. In contrast, NPM-ALK was shown to homo-oltqomerlse In
vivo and heterodlmerlse with normal NPM-ALK In addition to exhlbl1Jngkinase
activity in vivo. Furthermore) it was found that the portion of NP~;1present
In the fusion protein, shares 47% amino acid identity with the amlno-
terminus of nucleoplasmIn. These struoture-funotlon studies suggest that the
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'118 amino acid segment of NPM, and the corresponding segment of
nucleop!asmln, represent the minimal motif requlred for the homo-
ollgomerisatlon of these proteins. This aspect requtres further
expertmentatlon to determine more precisely the nature of this minimal
motif.
Immunosta.inlng experiments of a t(2;5)acontaining lymphoma cell line
revealed NPM~ALK to be localised within both the cytoplasmic and
nuotearznucleolar compartments. The normal shuttling function of NPM,
together with the observations that NPM and NPMNALK heterodlmerlse,
suggest that the nuclear location of the chimaera results from NPMN
mediated protein translocatton since the nuclear localisation signals of NPM
are not present In NPM-ALK. It was found that none of three different NPM-
ALK proteins lacking non-overlapplnq portions of the NPM segment was
present In the cell nucleus, However, NPM could be replaced in the fusion
protein with the portion of the TPR protein that activates the TPR-MET
fusion kinase by mediating dlrnerlsatlon through its leucine zipper motif. This
engineered TPR..ALI< hybrid protein, which transformed cells with essentially
equivalent potency to NPM-ALI<, was localised within the cytoplasm 01 ('j ~lIs.
These data indloate that the nuclear/nucleolar localisation of NPL ,-AU<,
which probCtuiy occurs because of transport via shuttll.1g aotivlty of NPM, Is
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not required for oncogenesis. Furthermore, the activation of the truncated
ALK protein by a completely heterologous oligomerisatlon domain suggests
that the functionally important role of the NPM segment of NPM·ALK in
transformation is restricted to the formation of ldnase-aotlve ollpomers ana
does not Involve tile alteration of normal NPM function. Since the presence
of NPM·ALK In the nucleus/r-rcleoll does not appear to lJe involved in
transformation, the function of the chlrnaerlo protein ir... 19 these cellular
compartments, if any, has yet to be determined.
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